<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420306498</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112677</dc:identifier><eid>1-s2.0-S0223523420306498</eid><prism:doi>10.1016/j.ejmech.2020.112677</prism:doi><pii>S0223-5234(20)30649-8</pii><dc:title>Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>206</prism:volume><prism:startingPage>112677</prism:startingpage><prism:pageRange>112677</prism:pagerange><articleNumber>112677</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-11-15</prism:coverdate><prism:coverDisplayDate>15 November 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Wei, Mingming</dc:creator><dc:creator>Xie, Maodun</dc:creator><dc:creator>Zhang, Zhen</dc:creator><dc:creator>Wei, Yujiao</dc:creator><dc:creator>Zhang, Juan</dc:creator><dc:creator>Pan, Hongli</dc:creator><dc:creator>Li, Benlong</dc:creator><dc:creator>Wang, Jingjing</dc:creator><dc:creator>Song, Yang</dc:creator><dc:creator>Chong, Chuangke</dc:creator><dc:creator>Zhao, Rui</dc:creator><dc:creator>Wang, Jiefu</dc:creator><dc:creator>Yu, Li</dc:creator><dc:creator>Yang, Guang</dc:creator><dc:creator>Yang, Cheng</dc:creator><dc:description>
                  Histone deacetylases (HDACs) inhibitors have demonstrated a great clinical achievement in hematological malignancies. However, the efficacy of HDACs inhibitors in treating solid tumors remains limited due to the complicated tumor microenvironment. In this study, we designed and synthesized a class of novel HDACs inhibitors based on the structure of flavones and isoflavones, followed by biological evaluation. To be specific, a lead compound 15a was discovered with strong anti-proliferative effects on a variety of solid tumor cells, especially for breast cancer cells with resistance to SAHA. Studies demonstrated that 15a could significantly inhibit the activity of HDAC 1, 2, 3 (class I) and 6 (class IIB), leading to a dose-dependent accumulation of acetylated histones and α-Tubulin, cell cycle arrest (G1/S phase) and apoptosis in breast cancer cells. Furthermore, the lead compound 15a could also antagonize the activation of STAT3 induced by HDACs inhibition in some breast cancer cells, which further reduced the level of pro-survive proteins in tumor cells and enhanced anti-tumor activity regulated by STAT3 signaling in vivo. Overall, our findings demonstrated that the novel compound 15a might be a HDACs inhibitor candidate, which could be used as promising chemotherapeutic agent for breast cancer.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>HDAC</dcterms:subject><dcterms:subject>STAT3 signaling pathway</dcterms:subject><dcterms:subject>Solid malignancies</dcterms:subject><dcterms:subject>Flavones</dcterms:subject><dcterms:subject>Hybrid</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420306498" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420306498" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="357" height="158" size="17590">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="535" size="105092">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="28" height="22" size="696">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="39" height="24" size="752">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="407" size="94466">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="30" height="24" size="710">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="300" size="60635">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="355" height="181" size="12188">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="275" height="245" size="25711">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="530" size="207782">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="541" size="123304">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="27" height="24" size="687">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="616" size="132121">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="474" size="43350">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc4.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="467" size="54746">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="208" size="23198">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="97" size="4651">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="205" height="164" size="16391">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="128" height="100" size="2018">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="175" height="108" size="2291">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="125" size="15990">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="137" height="108" size="2126">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="11305">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="112" size="4060">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="184" height="164" size="12544">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="164" size="31368">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="164" size="14993">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="122" height="108" size="2012">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="190" height="164" size="16874">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="sc4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="184" height="164" size="5202">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc4.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="218" height="164" size="6175">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="4694">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1583" height="699" size="144836">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="2367" size="853724">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="128" height="100" size="3310">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="175" height="108" size="4176">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="1802" size="765486">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="137" height="108" size="3696">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3150" height="1327" size="558940">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1575" height="804" size="99531">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1217" height="1085" size="188529">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="2345" size="1956481">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="2395" size="1068004">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="122" height="108" size="3436">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="2730" size="1105734">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="2099" size="345386">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="2071" size="431419">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="922" size="194780">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="8894225">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-mmc1.pdf?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1433328">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420306498-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85089482329</scopus-id><scopus-eid>2-s2.0-85089482329</scopus-eid><pubmed-id>32823005</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85089482329" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200801">2020-08-01</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200801">2020-08-01</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200819">2020-08-19</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200819">2020-08-19</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-10-15T16:42:30</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420306498</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30649-8</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420306498</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112677</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00195</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20201015">2020-10-15T17:37:52.023135Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20201115</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1596267127">2020-08-01T07:32:07.918063Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>206</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>206</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 206</xocs:vol-iss-suppl-text>
      <xocs:sort-order>16</xocs:sort-order>
      <xocs:first-fp>112677</xocs:first-fp>
      <xocs:article-number>112677</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112677</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20201115</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 November 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-11-15</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DESIGNSYNTHESISNOVELFLAVONEBASEDHISTONEDEACETYLASEINHIBITORSANTAGONIZINGACTIVATIONSTAT3INBREASTCANCER</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>WEI</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>M</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Total synthesis of lead compound 15a in gram scale</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Enzyme inhibitory activity <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Effect of compounds 15a and 15d on HDACs and the activation of STAT3</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Toxicity evaluation of compounds 15a and 15d</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>HDAC isoform selectivity profiling <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Tumor-type selectivity of compound <ce:bold>15a</ce:bold>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>15a</ce:bold> inhibited proliferation of breast cancer cells <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>15a</ce:bold> induced cell cycle arrest</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>15a</ce:bold> notably induced breast cancer cell apoptosis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.11</xocs:item-toc-label>
               <xocs:item-toc-section-title>Preliminary pharmacokinetic (PK) study of compound 15a in rats</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.12</xocs:item-toc-label>
               <xocs:item-toc-section-title>Preliminary hERG binding test of compound <ce:bold>15a</ce:bold> 
                  <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.13</xocs:item-toc-label>
               <xocs:item-toc-section-title>Preliminary Ames test of compound <ce:bold>15a</ce:bold> 
                  <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.14</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>15a</ce:bold> notably suppressed tumor growth <ce:italic>in vivo</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.15</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>15a</ce:bold> inhibited both HDACs and activation of STAT3 <ce:italic>in vivo</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of tested compounds</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell lines and cell culture</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>HDAC enzyme assay <ce:italic>in vitro</ce:italic>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cytotoxicity assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Colony formation assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cycle assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Apoptosis assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>PK study</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Animal study</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>3.1.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Notes</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>PESERICO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>10</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>WITT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>8</xocs:ref-first-fp>
            <xocs:ref-last-lp>21</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>WEST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>30</xocs:ref-first-fp>
            <xocs:ref-last-lp>39</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>KHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>94</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>FALKENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>673</xocs:ref-first-fp>
            <xocs:ref-last-lp>691</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>CONWAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>523</xocs:ref-first-fp>
            <xocs:ref-last-lp>524</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>MOSKOWITZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>ZENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>459</xocs:ref-first-fp>
            <xocs:ref-last-lp>473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>VANSTEENKISTE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>483</xocs:ref-first-fp>
            <xocs:ref-last-lp>488</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>BLUMENSCHEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>81</xocs:ref-first-fp>
            <xocs:ref-last-lp>87</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>LUU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>7138</xocs:ref-first-fp>
            <xocs:ref-last-lp>7142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>ROBEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2021</xocs:ref-first-fp>
            <xocs:ref-last-lp>2031</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>234</xocs:ref-first-fp>
            <xocs:ref-last-lp>248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>117</xocs:ref-first-fp>
            <xocs:ref-last-lp>128</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>59</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>54</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>KUJAWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>3367</xocs:ref-first-fp>
            <xocs:ref-last-lp>3377</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>OH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>95</xocs:ref-first-fp>
            <xocs:ref-last-lp>103</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>KUMAMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>17</xocs:ref-first-fp>
            <xocs:ref-last-lp>26</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>SELVENDIRAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>4826</xocs:ref-first-fp>
            <xocs:ref-last-lp>4834</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>SINGHGUPTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1675</xocs:ref-first-fp>
            <xocs:ref-last-lp>1684</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>104</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>AI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>100216</xocs:ref-first-fp>
            <xocs:ref-last-lp>100226</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>HONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1927</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>AHMED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>552</xocs:ref-first-fp>
            <xocs:ref-last-lp>564</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>GOBBI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>3662</xocs:ref-first-fp>
            <xocs:ref-last-lp>3669</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>196</xocs:ref-first-fp>
            <xocs:ref-last-lp>208</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>BEUTLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>2333</xocs:ref-first-fp>
            <xocs:ref-last-lp>2338</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>JUVALE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>115</xocs:ref-first-fp>
            <xocs:ref-last-lp>126</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>HASSAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>559</xocs:ref-first-fp>
            <xocs:ref-last-lp>580</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>HASSAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>111965</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>FERRARIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>3357</xocs:ref-first-fp>
            <xocs:ref-last-lp>3359</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>WEIX2020X112677</xocs:refkey3>
         <xocs:refkey4ai>WEIX2020X112677XM</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-08-19T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-08-19T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-07-23T06:15:33.647Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30649-8</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420306498</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420306498</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112677</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-10-15T17:37:52.023135Z</xocs:timestamp>
         <xocs:cover-date-start>2020-11-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/MAIN/application/pdf/483e114b7036c578268b041741d17972/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>4179484</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>20</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420306498-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/PREVIEW/image/png/19e85c90981fcbc4890ac86c404d78c3/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>58197</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc1/DOWNSAMPLED/image/jpeg/8c43d72fb480db5fa3ca98a7a6d71436/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17590</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>357</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr6/DOWNSAMPLED/image/jpeg/f7d8e46f0f714b2e72cd118a7b440e4e/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>105092</xocs:filesize>
               <xocs:pixel-height>535</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx5/DOWNSAMPLED/image/jpeg/c24f800df210a866a4192c2a91418633/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>696</xocs:filesize>
               <xocs:pixel-height>22</xocs:pixel-height>
               <xocs:pixel-width>28</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx2/DOWNSAMPLED/image/jpeg/f5909c66700a51390076e13aeb76f8ea/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>752</xocs:filesize>
               <xocs:pixel-height>24</xocs:pixel-height>
               <xocs:pixel-width>39</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr2/DOWNSAMPLED/image/jpeg/75a52a73c9c21733b7517d9770f4efc2/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>94466</xocs:filesize>
               <xocs:pixel-height>407</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx3/DOWNSAMPLED/image/jpeg/37f8bb60b8a611896e2dfe0a3fb7d066/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>710</xocs:filesize>
               <xocs:pixel-height>24</xocs:pixel-height>
               <xocs:pixel-width>30</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr1/DOWNSAMPLED/image/jpeg/c8b8da0c11816d7551f0d96fa1f5f131/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60635</xocs:filesize>
               <xocs:pixel-height>300</xocs:pixel-height>
               <xocs:pixel-width>711</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc2/DOWNSAMPLED/image/jpeg/e342f562a7d44e57ddb88451e7c156de/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>12188</xocs:filesize>
               <xocs:pixel-height>181</xocs:pixel-height>
               <xocs:pixel-width>355</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx1/DOWNSAMPLED/image/jpeg/30c9c6ce782fe5019ca10f6b303820c1/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25711</xocs:filesize>
               <xocs:pixel-height>245</xocs:pixel-height>
               <xocs:pixel-width>275</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr7/DOWNSAMPLED/image/jpeg/8f4554f3f86661bfbe7b2136fd25a6ab/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>207782</xocs:filesize>
               <xocs:pixel-height>530</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr3/DOWNSAMPLED/image/jpeg/524a07462822436113a44857560f7e25/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>123304</xocs:filesize>
               <xocs:pixel-height>541</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx4/DOWNSAMPLED/image/jpeg/2aa00f91ccf616e382128bf5985b2cff/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>687</xocs:filesize>
               <xocs:pixel-height>24</xocs:pixel-height>
               <xocs:pixel-width>27</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr4/DOWNSAMPLED/image/jpeg/da0843798ef70ac3f6c5633106d61245/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>132121</xocs:filesize>
               <xocs:pixel-height>616</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc4/DOWNSAMPLED/image/jpeg/712422f699517cd8ec54caf297894880/sc4.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43350</xocs:filesize>
               <xocs:pixel-height>474</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc3/DOWNSAMPLED/image/jpeg/4d90f694f61ee3f335e35047c2b28e6b/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>54746</xocs:filesize>
               <xocs:pixel-height>467</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr5/DOWNSAMPLED/image/jpeg/8b95b3d0f68a817b2505582ae1c37d5b/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23198</xocs:filesize>
               <xocs:pixel-height>208</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc1/THUMBNAIL/image/gif/461f7154f19cbb92861b116f06119d62/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4651</xocs:filesize>
               <xocs:pixel-height>97</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr6/THUMBNAIL/image/gif/1576079429b8d18ab556700da0d07007/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16391</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>205</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx5/THUMBNAIL/image/gif/871c160024a71973a9b831a7fcf99bd6/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2018</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx2/THUMBNAIL/image/gif/571fe81ccc82c969e403edeeded700cf/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2291</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr2/THUMBNAIL/image/gif/b890522f1876afc9666546a41f7f1c01/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15990</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx3/THUMBNAIL/image/gif/2de61cd21cde28a0fe94b5330f91db22/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2126</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>137</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr1/THUMBNAIL/image/gif/954d93790ad9e8127dc33512a54caec8/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11305</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc2/THUMBNAIL/image/gif/a9125dbab5b633a6383b8d69e83feeb0/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4060</xocs:filesize>
               <xocs:pixel-height>112</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx1/THUMBNAIL/image/gif/3a1ba81a3f8f783a435702e711a6df4e/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12544</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>184</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr7/THUMBNAIL/image/gif/e3f825bb81a3cd32cdb20c1f0e24b926/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>31368</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr3/THUMBNAIL/image/gif/5988c7f7c8c41ee33eacacd87c614d63/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14993</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx4/THUMBNAIL/image/gif/8c18c03dea5112f0d7a499f171a9e1bf/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2012</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>122</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr4/THUMBNAIL/image/gif/6de905a7b3a92bfe2e501b34e91b3747/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16874</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>190</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc4/THUMBNAIL/image/gif/5be30afae620b205caf1444c6c86ecc5/sc4.sml</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5202</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>184</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc3/THUMBNAIL/image/gif/e5a465450d5c95fac0f770efebaebb0a/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6175</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr5/THUMBNAIL/image/gif/021da0a0bf513edefe8b43fd61126e8f/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4694</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc1/HIGHRES/image/jpeg/64f7e7fccefb9e889007d8ee9daa3bde/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>144836</xocs:filesize>
               <xocs:pixel-height>699</xocs:pixel-height>
               <xocs:pixel-width>1583</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr6/HIGHRES/image/jpeg/7d28672f2c7f1a97d24814c7bab6b085/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>853724</xocs:filesize>
               <xocs:pixel-height>2367</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx5/HIGHRES/image/jpeg/3554b1b55c83eb431d5b716823184ee2/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3310</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx2/HIGHRES/image/jpeg/e92afb4ebe54c1aafeece0fb1bcc7bdb/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4176</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr2/HIGHRES/image/jpeg/33a4c74efbafff285debd0cb373148ac/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>765486</xocs:filesize>
               <xocs:pixel-height>1802</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx3/HIGHRES/image/jpeg/ca1a214d4e61bd85bcc4dd567fb1941a/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3696</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>137</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr1/HIGHRES/image/jpeg/a39523bd18a3b7d30627b7ec62d2ec4e/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>558940</xocs:filesize>
               <xocs:pixel-height>1327</xocs:pixel-height>
               <xocs:pixel-width>3150</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc2/HIGHRES/image/jpeg/b93f310593c7e1da3373878f014c7170/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>99531</xocs:filesize>
               <xocs:pixel-height>804</xocs:pixel-height>
               <xocs:pixel-width>1575</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx1/HIGHRES/image/jpeg/e1b88750bab0446c6e559f059611f7fb/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>188529</xocs:filesize>
               <xocs:pixel-height>1085</xocs:pixel-height>
               <xocs:pixel-width>1217</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr7/HIGHRES/image/jpeg/53c5fc1a1aba3d30259743a8d49b9fcb/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1956481</xocs:filesize>
               <xocs:pixel-height>2345</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr3/HIGHRES/image/jpeg/3bc3cd5ccc6fab0916644ab7843ab666/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1068004</xocs:filesize>
               <xocs:pixel-height>2395</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/fx4/HIGHRES/image/jpeg/e446ef0bda8e48b3dca6c94b9e5a6e32/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3436</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>122</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr4/HIGHRES/image/jpeg/166b61f0654c9b72b4155372739a8af0/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1105734</xocs:filesize>
               <xocs:pixel-height>2730</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc4/HIGHRES/image/jpeg/91da2adbdd7700f93045b5ad790b7321/sc4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>345386</xocs:filesize>
               <xocs:pixel-height>2099</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/sc3/HIGHRES/image/jpeg/2ec6fd2604f3bdba37c397bdf9365b78/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>431419</xocs:filesize>
               <xocs:pixel-height>2071</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/gr5/HIGHRES/image/jpeg/ca729eb2e262fd11a15f6b3fb5819f7e/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>194780</xocs:filesize>
               <xocs:pixel-height>922</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420306498/mmc1/MAIN/application/pdf/92661f97d7e854fdcede7f5fdf11589e/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>8894225</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420306498-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10DSM7S2WX0/MAIN/application/pdf/244e5360bdf10dfaac3d7b3c449c3edc/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>1433328</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112677</aid>
            <ce:article-number>112677</ce:article-number>
            <ce:pii>S0223-5234(20)30649-8</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112677</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Effects of Compounds <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold> on the Level of Acetylated H3, Acetylated α-Tubulin and p-STAT3 (A, B) MDA-MB-231 cells were respectively treated with indicated concentrations of SAHA, Apigenin, Compound <ce:bold>14a</ce:bold>, <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold> for 8 h. Then, cells were harvested. Western blot was used to detect targeted proteins.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420306498/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Compound <ce:bold>15a</ce:bold> Inhibited the Growth of Tumor Cells <ce:italic>in Vitro</ce:italic>. (A) MTT assay was used to determine the growth curves of MDA-MB-231 and 4T1 cells after treatment with compound <ce:bold>15a,</ce:bold> SAHA and Apigenin at indicated concentrations. (B) Representative images of the colony formation assay and (C) quantitative data analysis of colony numbers for compound <ce:bold>15a,</ce:bold> SAHA and Apigenin in MDA-MB-231 and 4T1 cell. Tumor cells were treated with indicated concentrations of compound <ce:bold>15a,</ce:bold> SAHA and Apigenin for seven days and the numbers of colony were calculated with image J. Data were presented as mean ± SD, Student’ T-test, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗ ∗∗∗P < 0.0001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420306498/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Effect of compound <ce:bold>15a</ce:bold> on cell cycle progression of tumor cells. (A) Flow cytometry of the DNA content of MDA-MB-231 and 4T1 cells following staining with propidium iodide. (B) The bar graph showed the proportions of tumor cells in G0/G1, S and G2/M phase respectively. Data were presented as mean ± SD, Student’ T-test, ∗P < 0.05, ∗∗P < 0.01. (C) Western blot of p21 protein from MDA-MB-231 and 4T1 cell lysates obtained after compound <ce:bold>15a</ce:bold> and SAHA treatment for 24 h. β-Actin was used as reference.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420306498/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Effect of Compound <ce:bold>15a</ce:bold> on Tumor Cell Apoptosis. (A) Flow cytometry of apoptosis in MDA-MB-231 and 4T1 cells treated with compound <ce:bold>15a,</ce:bold> SAHA and Apigenin for 72 h. (B) Quantitative analysis of apoptotic tumor cells. Data were presented as mean ± SD, Student’ T-test, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. (C) MDA-MB-231 cells were incubated with compound <ce:bold>15a</ce:bold> and SAHA for 48 h. Then, Western blot was used to evaluate the level of cleaved-PARP, cleaved-Caspase3, p53 and Bcl-2 members (Bcl-2 and Bax); β-Actin was used as reference.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420306498/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">PK study of compound <ce:bold>15a</ce:bold> in rats. (A) Compound <ce:bold>15a</ce:bold> plasma concentration−time curve in SD rats after a single PO administration of drug (20 mg/kg, mean ± SD, n = 3); (B) Compounds <ce:bold>15a</ce:bold> plasma concentration−time curve in SD rats after a single IV administration of drug (20 mg/kg, mean ± SD, n = 3).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420306498/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">
                     <ce:italic>In Vivo</ce:italic> Antitumor Efficacy of Compound <ce:bold>15a.</ce:bold> (A) Balb/c mice were subcutaneously injected with 4T1 cells, which were further treated with compound <ce:bold>15a</ce:bold> and SAHA at indicated dose for 22 days. Tumor volume curves for 4T1 xenografts (left), tumor weigh (middle), body weight of mice (right). (B) Balb/c nude mice were subcutaneously injected with MDA-MB-231 cells, followed by treatment with <ce:bold>15a</ce:bold> and SAHA at indicated dose for 34 days. Tumor volume curves for MDA-MB-231 xenografts (left), tumor weigh (middle), body weight of mice (right). (C, D) Images of tumor xenografts excised from mice model. Data were presented as mean ± SD, n = 5, Student’ T-test, ∗∗P < 0.01, ∗∗∗P < 0.001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420306498/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Compound <ce:bold>15a</ce:bold> Inhibited HDACs and Activation of STAT3 <ce:italic>in Vivo</ce:italic>
                  </ce:simple-para>
                  <ce:simple-para id="fspara0045" view="all">Tumor tissue lesions (n = 5) from MDA-MB-231 and 4T1 xenograft model were stained with monoclonal antibody against Ac-H3, Ac-α-Tubulin, cleaved-Caspase3, p-STAT3<ce:sup loc="post">Tyr705</ce:sup> and STAT3, and subsequently photographed (200X or 400X).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523420306498/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0050" view="all">Design of novel HDACs Inhibitors Based on Structure of Natural Flavones and Isoflavones.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523420306498/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0055" view="all">Structure of Some Commercially Available Natural Flavones and Isoflavones.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S0223523420306498/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0060" view="all">Preparation of HDACs Inhibitors Based on Structure of Flavones and Isoflavones.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:href="pii:S0223523420306498/sc3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch4">
               <ce:label>Scheme 4</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0065" view="all">Gram-scale Synthesis of Lead Compound <ce:bold>15a</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Scheme 4</ce:alt-text>
               <ce:link locator="sc4" xlink:href="pii:S0223523420306498/sc4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0010" view="all">Structure of potential HDACs inhibitors based on structure of flavones and isoflavones.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Table 1</ce:alt-text>
               <tgroup cols="7">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Formula of Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">No. of Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">n</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">m</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R [<cross-ref id="crosref0305" refid="bib1">1</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R [<cross-ref id="crosref0310" refid="bib3">3</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R [<cross-ref id="crosref0315" refid="bib4">4</cross-ref>]</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8g</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8h</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8i</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8j</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8k</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8l</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx2" xlink:href="pii:S0223523420306498/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0080" role="short">Image 2</alt-text>
                           </inline-figure>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523420306498/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0085" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523420306498/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523420306498/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0015" view="all">Enzyme inhibition of potential HDACs inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0100" role="short">Table 2</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Enzyme Activity IC<inf loc="post">50</inf> (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Enzyme Activity IC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>SAHA</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.259 ± 0.028</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.331 ± 0.464</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.053 ± 0.009</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.025 ± 0.001</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.088 ± 0.008</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.732 ± 0.036</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.402 ± 0.063</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.676 ± 0.033</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8g</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.531 ± 0.430</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.065 ± 0.007</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8h</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.246 ± 0.465</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.025 ± 0.006</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8i</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.053 ± 0.006</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8j</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.297 ± 0.013</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.225 ± 0.046</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8k</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.930 ± 0.096</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.590 ± 0.057</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8l</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.615 ± 0.016</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.133 ± 0.018</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.710 ± 0.067</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Apgenin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0020" view="all">IC<ce:inf loc="post">50</ce:inf> > 10 μmol/L indicated no significant inhibition; IC<ce:inf loc="post">50</ce:inf> was determined from three independent experiments.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0025" view="all">Isoform selectivity of compound <ce:bold>15a</ce:bold> against the class I, II, and IV HDAC enzymes.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0105" role="short">Table 3</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col3" namest="col1" role="colgroup">IC<inf loc="post">50</inf> ± SD (nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col6" namest="col4" role="colgroup">IC<inf loc="post">50</inf> ± SD (nM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Isoform</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Class</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound 15a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Isoform</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Class</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound 15a</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35.95 ± 4.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IIA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10000 (43% at 10 μM)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">58.46 ± 8.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2500 ± 729</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">79.21 ± 10.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IIA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10000 (26% at 10 μM)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IIA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">306.53 ± 43.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IIB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">246.53 ± 61.8</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IIA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10000 (38% at 10 μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IV</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">179.35 ± 33.0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IIB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25.46 ± 3.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0030" view="all">HDAC enzymes were tested in a 10-dose IC<ce:inf loc="post">50</ce:inf>.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0035" view="all">Cytotoxic activity of compound <ce:bold>15a</ce:bold> Against diverse cancer cell lines.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0110" role="short">Table 4</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Cell line</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Cell Description</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col4" namest="col3" role="colgroup">IC<inf loc="post">50</inf> value (μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">SAHA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound 15a</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4T1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Triple negative breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.317 ± 0.269</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.986 ± 0.126</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.585 ± 0.365</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.050 ± 0.179</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-468</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.03 ± 1.226</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.397 ± 0.744</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BT-549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.670 ± 1.480</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.130 ± 0.941</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sum-159</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.381 ± 0.319</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.277 ± 0.024</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HER2 negative breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.798 ± 1.672</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.697 ± 0.793</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">T47D</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.243 ± 0.204</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.529 ± 0.165</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BCAP-37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.098 ± 0.816</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.278 ± 0.591</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B16F10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Melanoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.067 ± 0.558</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.510 ± 0.021</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A375</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.827 ± 0.420</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.177 ± 0.150</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PLC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hepatocarcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.534 ± 0.173</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.582 ± 0.065</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HepG2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.265 ± 0.692</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.158 ± 0.301</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SMMC7721</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.990 ± 0.865</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.530 ± 0.047</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bel-7402</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.207 ± 1.005</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.312 ± 0.390</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lung adenocarcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.360 ± 0.209</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.076 ± 0.106</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCI–H460</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Large cell lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.136 ± 0.492</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.725 ± 0.133</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCI-1581</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.501 ± 0.772</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.322 ± 0.519</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PANC-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pancreatic cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PC-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.459 ± 0.829</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.919 ± 0.446</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">293T</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human kidney cell</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.221 ± 0.467</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LO-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human liver cell</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0040" view="all">IC<ce:inf loc="post">50</ce:inf> > 10 μmol/L indicated no significant inhibition; IC<ce:inf loc="post">50</ce:inf> was determined from three independent experiments. MTT assay was used to determine the cytotoxic effect of compound <ce:bold>15a</ce:bold> and SAHA after 48 h incubation.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl5" rowsep="0">
               <ce:label>Table 5</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="tspara0045" view="all">Preliminary pharmacokinetic (PK) parameters of compound <ce:bold>15a</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0115" role="short">Table 5</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">PK Parameters</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">P.O. 20 mg/kg</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">I.V. 20 mg/kg</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C<inf loc="post">max</inf> (μg/L)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1278 ± 215</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2183 ± 240</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AUC<inf loc="post">(0-∞)</inf> (μg/L)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1641 ± 15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2837 ± 169</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tmax (h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.333 ± 0.176</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.083 ± 0.001</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t1/2 (h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.249 ± 0.002</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.422 ± 0.103</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MRT (h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.097 ± 0.079</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.249 ± 0.084</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">F%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">57.8%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl6" rowsep="0">
               <ce:label>Table 6</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="tspara0050" view="all">hERG Binding Test of Compound <ce:bold>15a</ce:bold> 
                     <ce:italic>in vitro</ce:italic>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0120" role="short">Table 6</ce:alt-text>
               <tgroup cols="2">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">hERG/IC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.201 ± 42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SAHA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.322 ± 13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cisplatin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.298 ± 24</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl7" rowsep="0">
               <ce:label>Table 7</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="tspara0055" view="all">Ames test of compound <ce:bold>15a</ce:bold> 
                     <ce:italic>in vitro</ce:italic>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0125" role="short">Table 7</ce:alt-text>
               <tgroup cols="7">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TA97a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TA98</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TA100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TA1535</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TA1537</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">WP2 uvrA (pKM 101)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Positive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Positive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SAHA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Positive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Positive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Negtive</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420306498-f2e4dba56fcc83c114ac0fccfa723117">
                  <ce:given-name>Mingming</ce:given-name>
                  <ce:surname>Wei</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420306498-99d8a4f1e98129fbb3b55937231f7e1c">
                  <ce:given-name>Maodun</ce:given-name>
                  <ce:surname>Xie</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420306498-2fa25687a4ee18040baf2a2bf54214a7">
                  <ce:given-name>Zhen</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420306498-b334781a4aba175767caed5194b881ae">
                  <ce:given-name>Yujiao</ce:given-name>
                  <ce:surname>Wei</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0045" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420306498-79a63fbb4c5d09124cb30b1694676216">
                  <ce:given-name>Juan</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0055" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523420306498-923431143a13d0c4b70db974fe1e03ca">
                  <ce:given-name>Hongli</ce:given-name>
                  <ce:surname>Pan</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0065" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523420306498-cab049a0fc116cf4eec7159c1b79d8a0">
                  <ce:given-name>Benlong</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523420306498-e030e76960dcfcdacfaaf5f3fedafdd1">
                  <ce:given-name>Jingjing</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0075" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523420306498-f0bfa7919136b232007e5da69cf43868">
                  <ce:given-name>Yang</ce:given-name>
                  <ce:surname>Song</ce:surname>
                  <ce:cross-ref id="crosref0080" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10" author-id="S0223523420306498-cd211d70b78bacaf3666a2af3bcc2902">
                  <ce:given-name>Chuangke</ce:given-name>
                  <ce:surname>Chong</ce:surname>
                  <ce:cross-ref id="crosref0085" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au11" author-id="S0223523420306498-9c47205124fe37c118f7d1640b890832">
                  <ce:given-name>Rui</ce:given-name>
                  <ce:surname>Zhao</ce:surname>
                  <ce:cross-ref id="crosref0090" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au12" author-id="S0223523420306498-e57ecbd827b0d817c27e621238415f4a">
                  <ce:given-name>Jiefu</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0095" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0100" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au13" author-id="S0223523420306498-73107b8da94ee3c6e8912a3d367f6951">
                  <ce:given-name>Li</ce:given-name>
                  <ce:surname>Yu</ce:surname>
                  <ce:cross-ref id="crosref0105" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0110" refid="cor3">
                     <ce:sup loc="post">∗∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au14" orcid="0000-0002-1773-9392" author-id="S0223523420306498-a692a9f3d122fe7a1c0cd4b8b6209edc">
                  <ce:given-name>Guang</ce:given-name>
                  <ce:surname>Yang</ce:surname>
                  <ce:cross-ref id="crosref0115" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0120" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au15" author-id="S0223523420306498-37c3aefd518d52ec69fb666f56d4df43">
                  <ce:given-name>Cheng</ce:given-name>
                  <ce:surname>Yang</ce:surname>
                  <ce:cross-ref id="crosref0125" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0130" refid="cor4">
                     <ce:sup loc="post">∗∗∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420306498-58cbf0702dd529100519e4d7d55968b6">
                  <ce:label>a</ce:label>
                  <ce:textfn>The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300071, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>The State Key Laboratory of Medicinal Chemical Biology</sa:organization>
                     <sa:organization>College of Pharmacy</sa:organization>
                     <sa:organization>Nankai University</sa:organization>
                     <sa:city>Tianjin</sa:city>
                     <sa:postal-code>300071</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300071, People’s China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420306498-cf165000b1cafa0af5ff6bfe82521ae4">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Hematology and Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Hematology and Oncology</sa:organization>
                     <sa:organization>International Cancer Center</sa:organization>
                     <sa:organization>Shenzhen University General Hospital</sa:organization>
                     <sa:organization>Shenzhen University Health Science Center</sa:organization>
                     <sa:address-line>Xueyuan AVE 1098</sa:address-line>
                     <sa:address-line>Nanshan District</sa:address-line>
                     <sa:city>Shenzhen</sa:city>
                     <sa:state>Guangdong</sa:state>
                     <sa:postal-code>518000</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Department of Hematology and Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, P.R. China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523420306498-bc09622cc13f7ce455e32a244468db41">
                  <ce:label>c</ce:label>
                  <ce:textfn>Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment</sa:organization>
                     <sa:organization>Tianjin Lung Cancer Institute</sa:organization>
                     <sa:organization>Tianjin Medical University General Hospital</sa:organization>
                     <sa:city>Tianjin</sa:city>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, P.R. China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff4" affiliation-id="S0223523420306498-85cbd8c343d33b2ab59fe921e0391706">
                  <ce:label>d</ce:label>
                  <ce:textfn>Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Tianjin Medical University Cancer Institute and Hospital</sa:organization>
                     <sa:organization>National Clinical Research Center for Cancer</sa:organization>
                     <sa:organization>Tianjin’s Clinical Research Center for Cancer</sa:organization>
                     <sa:organization>Key Laboratory of Cancer Prevention and Therapy</sa:organization>
                     <sa:city>Tianjin</sa:city>
                     <sa:postal-code>300060</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0025">Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, P.R. China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor3">
                  <ce:label>∗∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor4">
                  <ce:label>∗∗∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="4" month="6" year="2020"/></ce:date-received>
            <ce:date-revised day="17" month="7" year="2020"/></ce:date-revised>
            <ce:date-accepted day="18" month="7" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Histone deacetylases (HDACs) inhibitors have demonstrated a great clinical achievement in hematological malignancies. However, the efficacy of HDACs inhibitors in treating solid tumors remains limited due to the complicated tumor microenvironment. In this study, we designed and synthesized a class of novel HDACs inhibitors based on the structure of flavones and isoflavones, followed by biological evaluation. To be specific, a lead compound <ce:bold>15a</ce:bold> was discovered with strong anti-proliferative effects on a variety of solid tumor cells, especially for breast cancer cells with resistance to SAHA. Studies demonstrated that <ce:bold>15a</ce:bold> could significantly inhibit the activity of HDAC 1, 2, 3 (class I) and 6 (class IIB), leading to a dose-dependent accumulation of acetylated histones and α-Tubulin, cell cycle arrest (G1/S phase) and apoptosis in breast cancer cells. Furthermore, the lead compound <ce:bold>15a</ce:bold> could also antagonize the activation of STAT3 induced by HDACs inhibition in some breast cancer cells, which further reduced the level of pro-survive proteins in tumor cells and enhanced anti-tumor activity regulated by STAT3 signaling <ce:italic>in vivo</ce:italic>. Overall, our findings demonstrated that the novel compound <ce:bold>15a</ce:bold> might be a HDACs inhibitor candidate, which could be used as promising chemotherapeutic agent for breast cancer.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420306498/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>HDAC</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>STAT3 signaling pathway</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Solid malignancies</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Flavones</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Hybrid</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">As a family of epigenetic enzymes, histone deacetylases (HDACs) can remove acetyl groups from lysine on histones and non-histone proteins, playing an essential role on controlling the transcription of genes and protein stability, which are involved in cell cycle progression, cell differentiation, cell apoptosis, angiogenesis and immune-regulation [<ce:cross-refs id="crosrefs0010" refid="bib1 bib2 bib3 bib4 bib5">1–5</ce:cross-refs>]. Functional dysregulations of HDACs have been regarded as a key trigger of various human cancers, thus representing a promising antitumor drug target [<ce:cross-ref id="crosref0135" refid="bib6">6</ce:cross-ref>]. Moreover, part of histone deacetylases (HDACs) inhibitors approved by the US Food and Drug Administration (FDA) have brought great clinical benefits in certain types of hematological malignancies, such as T-cell lymphoma and multiple myeloma [<ce:cross-ref id="crosref0140" refid="bib7">7</ce:cross-ref>]. However, the efficacy of HDACs inhibitors (such as SAHA) in treating solid tumors remains limited due to diverse resistance mechanisms [<ce:cross-refs id="crosrefs0015" refid="bib8 bib9 bib10 bib11">8–11</ce:cross-refs>].</ce:para>
                  <ce:para id="p0030" view="all">Activation of the signal transducer and activator of transcription (STAT) pathway has been linked to SAHA resistance in lymphoma [<ce:cross-ref id="crosref0145" refid="bib12">12</ce:cross-ref>]. The latest study also elucidated SAHA could upregulate the expression of leukemia inhibitory factor receptor (LIFR) through epigenetic modification of its promoter, leading to the activation of IL-6-LIFR-JAK-STAT3 pathway. It subsequently reduced the response of some breast cancer cells to chemotherapeutics, including HDACs inhibitors themselves [<ce:cross-ref id="crosref0150" refid="bib8">8</ce:cross-ref>]. To figure out the reason, firstly, activation of STAT3 promotes the growth of tumor cells by regulating key target genes involved in modulating cellular proliferation and metabolism, suppressing apoptosis, and responding to hypoxia [<ce:cross-ref id="crosref0155" refid="bib13">13</ce:cross-ref>]. Furthermore, immunosuppressive factors mediated by STAT3 activation in the tumor microenvironment (such as IL-6, IL-10, TGF-β, and VEGF) stimulates positive-feedback amplification of STAT3 activation in both tumor cells and tumor-infiltrating immune cells [<ce:cross-refs id="crosrefs0020" refid="bib14 bib15 bib16 bib17 bib18">14–18</ce:cross-refs>]. It could result in complex crosstalk between cancer cells and immune cells. This process could increase growth and survival of tumor cell, and diminish anti-tumor immunity. Collectively, upregulation of STAT3 induced by treatment of HDACs inhibitors is observed as an inevitable hindrance for the clinical application of HDACs inhibitors in some solid tumors. Therefore, as a possible solution, combinations between HDACs inhibition and antagonism of the oncogenic signaling pathways upstream of STAT3 might provide a promising and novel approach for chemotherapy of some solid malignancies.</ce:para>
                  <ce:para id="p0035" view="all">Clinically, drug cocktails have been widely used in cancer therapy. However, drug combinations are usually accompanied by complicated dose or schedule designs and might also cause safety problem due to the complexity of metabolism. Alternatively, the development of bifunctional with dual antagonist of STAT3 signaling and HDACs activity seems more feasible. To this end, it is considered as a good option by seeking and developing anti-cancer drug molecules from natural origins. The flavones and isoflavones are a class of promising anti-cancer natural products, which could block oncogenic signaling pathways upstream of STAT3 through different mechanisms in various cancer cells [<ce:cross-refs id="crosrefs0025" refid="bib19 bib20 bib21 bib22 bib23 bib24 bib25">19–25</ce:cross-refs>]. Based on the structure of flavones, there have been multiple studies concerning the structural modification and improvement of their anti-tumor activities [<ce:cross-refs id="crosrefs0030" refid="bib26 bib27 bib28 bib29 bib30 bib31 bib32">26–32</ce:cross-refs>]. Herein, based on the structure of flavones, novel HDACs inhibitors which also antagonize STAT3 activation are designed, synthesized and biologically screened. A lead compound has been identified, showing excellent potency in combinational treatment of various types of solid tumors cells, especially for triple-negative breast cancer subset <ce:italic>in vivo</ce:italic>.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0040" view="all">Based on the structure of flavones and designed according to molecular hybrid principle, a series of novel a series of novel STAT3 pathway-HDACs dual inhibitors were prepared according to synergistic effect between the two targets (<ce:cross-ref id="crosref0160" refid="sch1">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>). HDACs inhibitors (such as vorinostat) generally consisted of a hydrophobic capping group, a hydrophobic linker and a zinc-binding group (hydroxamic acid or benzamide). The general idea was that capping group was flexible, which could, thus, be replaced by other moieties to generate various HDACs inhibitors. The A ring of flavones and isoflavones seemed to be the ideal capping groups for designing HDACs inhibitors.</ce:para>
                     <ce:para id="p0045" view="all">The synthetic approaches were generally straightforward. Initially, commercially available natural flavones and isoflavones were used as starting material (<ce:cross-ref id="crosref0165" refid="sch2">Scheme 2</ce:cross-ref>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>). Firstly, starting from flavones <ce:bold>1</ce:bold>, <ce:bold>2</ce:bold> and <ce:bold>3</ce:bold> for instance, they reacted with various bromide substituted fatty acid esters <ce:bold>6a-f</ce:bold> in the presence of K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> in DMF (<ce:cross-ref id="crosref0170" refid="sch3">Scheme 3</ce:cross-ref>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>). The resulting esters <ce:bold>7</ce:bold> were then converted into hydroxamic acids <ce:bold>8</ce:bold> according to the reported method in high yield [<ce:cross-ref id="crosref0175" refid="bib33">33</ce:cross-ref>]. Meanwhile, using A ring of isoflavones as capping groups, natural product biochanin A (<ce:bold>4</ce:bold>) and formononetin (<ce:bold>5</ce:bold>) reacted with bromide compounds <ce:bold>9a-c</ce:bold> to yield acetyl protected hydroxamic acids <ce:bold>10</ce:bold>. After cleavage the acetyl group under mild acidic conditions, HDACs inhibitors <ce:bold>11</ce:bold> were delivered in almost quantity yield. Derivatives <ce:bold>12</ce:bold> from apigenin were mixed with 2-Chloroethyldimethylamine or 3-Chloropropyldimethylamine in acetone under reflux conditions to give rise to corresponding hydroxamic acid compounds. The same hydroxamic acid formation reaction was used to furnish the HDACs inhibitors <ce:bold>15</ce:bold>. Compound <ce:bold>16</ce:bold>, also derived from apigenin, reacted with dibromoethane and was subjected to various diamines to provide precursor <ce:bold>19</ce:bold>, which was then converted into corresponding hydroxamic acid products. Finally, both compounds <ce:bold>15</ce:bold> and <ce:bold>20</ce:bold> were prepared as stable and soluble hydrochloride salts (Please find the structure of all analogues from <ce:cross-ref id="optMfu0Wy4oY4" refid="tbl1">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Total synthesis of lead compound 15a in gram scale</ce:section-title>
                     <ce:para id="p0050" view="all">The synthesis started from phloroglucinol <ce:bold>21</ce:bold>. By Friedel-Crafts acylation reaction, acetyl group was constructed in 60%. Methylation intermediate <ce:bold>22</ce:bold> with methyl toluenesulfonate delivered compound <ce:bold>23</ce:bold>. Aldol reaction followed by dehydration provided enone <ce:bold>25</ce:bold> in 62% yield. Flavone core was then obtained by an Iodine-catalyzed cyclization within DMSO. Cleavage of benzyl group under Pd-catalyzed hydrogenation, and subjection of the resulting product <ce:bold>27</ce:bold> to mixing with 2-Dimethylaminoethyl chloride hydrochloride <ce:bold>28</ce:bold> afforded the compound <ce:bold>29</ce:bold>. Deprotection of methyl ether within melting pyridine hydrochloride followed by reaction with bromide <ce:bold>31</ce:bold> to yield the ester <ce:bold>32</ce:bold>. Amide formation by simply stirring <ce:bold>32</ce:bold> with hydroxylamine in methanol furnished yellow solid <ce:bold>33</ce:bold> quantitively. The final lead compound <ce:bold>15a</ce:bold> was a hydrochloride salt, which was provided by reaction with <ce:bold>33</ce:bold> and 1 M HCl in methanol. The whole synthesis had 10 linear steps with 3.3% overall yield. Approximately 5 g of compound <ce:bold>15a</ce:bold> was prepared in our lab (<ce:cross-ref id="optQV6tp8cKKJ" refid="sch4">Scheme 4</ce:cross-ref>
                        <ce:float-anchor refid="sch4"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Enzyme inhibitory activity <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0055" view="all">The enzyme inhibitory activity of HDACs inhibitors was assayed against whole HeLa cells extract, and SAHA (Vorinostat, a listed HADCs inhibitor) was used as reference. As shown in <ce:cross-ref id="crosref0190" refid="tbl2">Table 2</ce:cross-ref>
                        <ce:float-anchor refid="tbl2"/></ce:float-anchor>, analogs (compound <ce:bold>8d-f</ce:bold>, <ce:bold>8j-l</ce:bold>) derived from flavones, such as Chrysin and Apigenin, exhibited excellent enzyme inhibitory activity. While analogs (compound <ce:bold>8g-I, 11b-f</ce:bold>) derived from isoflavones, such as Formononetin and biochanin A, harbored low inhibitory activity. However, compound <ce:bold>8d</ce:bold> and <ce:bold>8e</ce:bold> were almost insoluble in aqueous buffer. In addition, compounds <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold>, stable and soluble hydrochloride salts, significantly improved the inhibitory activity of HDACs among all of the water-soluble analogs (compound <ce:bold>15a-f, 20a-d</ce:bold>). Finally, compound <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold> were selected for further evaluation.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Effect of compounds 15a and 15d on HDACs and the activation of STAT3</ce:section-title>
                     <ce:para id="p0060" view="all">To further determine whether the two selected compounds inhibited both HDACs and p-STAT3 in tumor cells, Western blot was performed. Briefly, as shown in <ce:cross-ref id="crosref0195" refid="fig1">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig1"/></ce:float-anchor>A, MDA-MB-231 cells were treated with different concentrations for 8 h. SAHA, Apigenin and its ester analogs were used as reference control. As a result, compound <ce:bold>15a</ce:bold>, <ce:bold>15d</ce:bold> and SAHA dramatically increased the abundance of acetylated histone 3 and α-Tubulin in a dose-dependent manner. By contrast, Apigenin and its ester analog <ce:bold>14a</ce:bold> had no effect on HDACs. These results indicated the effects on HDACs were mainly blocked by hydroxamic acids motif <ce:italic>in vitro</ce:italic>. Treatment of SAHA could cause continuous activation of the phosphorylation of STAT3 in response to increasing concentrations. It was consistent with the result of previous studies [<ce:cross-ref id="crosref0200" refid="bib8">8</ce:cross-ref>]. Further results demonstrated that apigenin could antagonize this upregulation. Meanwhile, Apigenin analog <ce:bold>14a</ce:bold> was exhibited more potent inhibition against p-STAT3 than Apigenin. Alternatively, when the cancer cells were treated by compound <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold> (<ce:cross-ref id="crosref0205" refid="fig1">Fig. 1</ce:cross-ref>B), the phosphorylation level of STAT3 firstly arose, and then decreased in a dose-dependent manner. For the possible mechanism, initially, in a low drug concentration, the compensatory activation effect of STAT3 signaling caused by inhibition of HDACs was dominated. With increasing the concentration of <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold>, antagonistic effects of STAT3-upstream pathway started playing more vital role. Taken together, our results confirmed that the compound <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold> could remarkably inhibit the activities of both HDACs and STAT3 in tumor cells at an optimal dose.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0060">Toxicity evaluation of compounds 15a and 15d</ce:section-title>
                     <ce:para id="p0065" view="all">Based on the results of enzyme activity assays and Western blot, two compounds <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold> were screened out with improved inhibitory activities on HDACs and STAT3 activation. As a preliminary toxicological study, C57/BL6 mice were treated with both compounds. To be specific, animals were intraperitoneally injected with these compounds in a single dose (300 mg/kg, n = 5). All mice treated with compound <ce:bold>15d</ce:bold> died within 24 h, indicating the extreme toxicity of compound <ce:bold>15d</ce:bold>. By contrast, the mice administered with compound <ce:bold>15a</ce:bold> were well tolerated. Subsequently, a 20-day oral chronic toxicity study was conducted at 50 mg/kg with both compounds <ce:bold>15a</ce:bold> and <ce:bold>15d</ce:bold> (dosed one daily, n = 5). As a result, all animals survived in compound <ce:bold>15a</ce:bold> group. Two animals of group <ce:bold>15d</ce:bold> were dead. These results suggested that compound <ce:bold>15a</ce:bold> might be safer and more suitable for further investigation <ce:italic>in vivo</ce:italic>.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0065">HDAC isoform selectivity profiling <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0070" view="all">To fully understand the selectivity of compound <ce:bold>15a</ce:bold> against HDACs, HDACs family profiles of each isoform were assessed by functional kinase enzyme assays. As shown in <ce:cross-ref id="crosref0210" refid="tbl3">Table 3</ce:cross-ref>
                        <ce:float-anchor refid="tbl3"/></ce:float-anchor>, For class I HDACs, compound <ce:bold>15a</ce:bold> showed selectivity for HDAC8 which had approximately 80-fold less inhibitory activity (versus HDAC1), with a dose-increasing nanomolar potency against HDAC1, HDAC2 and HDAC3 (35.95–79.21 nM). As observed for class II HDACs, compound <ce:bold>15a</ce:bold> was quite potent for class IIB HDACs, especially for HDAC6 (IC<ce:inf loc="post">50</ce:inf> = 25.46 nM ± 3.85). While inhibition of class IIA HDACs was only seen at concentrations above 10 μM, except for HDAC4. In addition, compound <ce:bold>15a</ce:bold> had moderate affinity to HDAC11. In summary, our data indicated compound <ce:bold>15a</ce:bold> showed approximately equal nanomolar affinity to HDAC1, 2, 3 and 6, and had much weaker inhibitory activity against other HDACs. As profiles shown, HDAC1, 2, 3, and 6 have important functions in tumor progression. These results suggested compound <ce:bold>15a</ce:bold> possessed potent cytotoxic activity to tumor cells.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0070">Tumor-type selectivity of compound <ce:bold>15a</ce:bold>
                     </ce:section-title>
                     <ce:para id="p0075" view="all">In order to obtain the evidence for tumor-type selectivity, the IC<ce:inf loc="post">50</ce:inf> values of compound <ce:bold>15a</ce:bold> were further detected on a panel of cancer cell lines using standard MTT assay. SAHA was selected as reference control. As shown in <ce:cross-ref id="crosref0215" refid="tbl4">Table 4</ce:cross-ref>
                        <ce:float-anchor refid="tbl4"/></ce:float-anchor>, compound <ce:bold>15a</ce:bold> exhibited excellent anti-proliferative activity against a broad spectrum of human solid cancer cell lines, including breast cancer, melanoma, hepatocarcinoma, lung cancer and pancreatic cancer. Importantly, compound <ce:bold>15a</ce:bold> exhibited a more potent anti-proliferative effect than SAHA in most human cancer cell lines. Especially, the anti-proliferative activity of compound <ce:bold>15a</ce:bold> was at least 2–3 folds more potent than SAHA in breast cancer cell lines with resistance to HDACs inhibitors, such as 4T1, MDA-MB-231, MDA-MB-468, BT-549 and MCF-7, indicating that compound <ce:bold>15a</ce:bold> may be a potential HDAC inhibitor which was beneficial to the treatment of breast cancer in which STAT3 would be activated by HDACs inhibition [<ce:cross-ref id="crosref0220" refid="bib8">8</ce:cross-ref>]. Consequently, we focused on the investigation of the anti-tumor activities of compound <ce:bold>15a</ce:bold> against triple-negative breast cancer. Compound <ce:bold>15a</ce:bold> had almost no inhibitory effect against 293T and LO-2 cells. It indicated compound <ce:bold>15a</ce:bold> might be an ideal agent specializing in killing tumor cells without or slightly affection on normal cells.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0075">Compound <ce:bold>15a</ce:bold> inhibited proliferation of breast cancer cells <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0080" view="all">For further anti-proliferative evaluation of compound <ce:bold>15a</ce:bold>, MTT assay was used to detect the growth curve of tumor cells treated with compound <ce:bold>15a.</ce:bold> SAHA and Apigenin were selected as reference control. As shown in <ce:cross-ref id="crosref0225" refid="fig2">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>A, both of compound <ce:bold>15a</ce:bold> and SAHA drastically reduced the growth rate of two triple-negative breast cancer cells, MDA-MB-231 and 4T1, in a dose-dependent manner. Compound <ce:bold>15a</ce:bold> demonstrated more potent than compound SAHA <ce:italic>in vitro</ce:italic>. Treatment of Apigenin showed no effect in low concentration. Consistent with the above results, fewer and smaller colonies were observed in groups treated with compound <ce:bold>15a</ce:bold> and SAHA in a dose-dependent manner. Apigenin was again failed in same concentration (<ce:cross-ref id="crosref0230" refid="fig2">Fig. 2</ce:cross-ref>B and C). Taken together, compound <ce:bold>15a</ce:bold> could more remarkably inhibit the growth of triple-negative breast cancer cells in a dose-dependent manner <ce:italic>in vitro</ce:italic>, comparison with SAHA and apigenin.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.9" view="all">
                     <ce:label>2.9</ce:label>
                     <ce:section-title id="sectitle0080">Compound <ce:bold>15a</ce:bold> induced cell cycle arrest</ce:section-title>
                     <ce:para id="p0085" view="all">To examine whether anti-proliferative potency of compound <ce:bold>15a</ce:bold> partly resulted from cell cycle arrest induced by HDACs inhibition, we next investigated the cell cycle kinetics in MDA-MB-231 and 4T1 cell lines. Tumor cells were firstly synchronized to G0/G1 phase through starvation for 24 h, and tumor cells were then incubated with complete medium with various concentrations of compound <ce:bold>15a</ce:bold>, SAHA and DMSO for 24 h, followed by flow cytometry to determine the proportion of cells in some phase of cell cycle. As shown in <ce:cross-ref id="crosref0235" refid="fig3">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>A and B, starvation rendered most tumor cells into G0/G1 phase, and then tumor cells treated with DMSO normally distributed in every phase of cell cycle. On the contrary, tumor cells incubated with compound <ce:bold>15a</ce:bold> had a significant G1 accumulation in a dose-dependent manner. And compound <ce:bold>15a</ce:bold> exhibited approximately equal effects on G1 phase arrest to reference compound SAHA under the same concentration. The tumor suppressor protein p21 was frequently involved in G1 phase arrest and was known to be induced by HDACs inhibition. To determine whether G1 phase arrest caused by compound <ce:bold>15a</ce:bold> is associated with upregulation of p21 protein, Western blotting of protein samples from MDA-MB-231 and 4T1 cell lines was performed. Treatment with compound <ce:bold>15a</ce:bold> resulted in increased p21 expression in a dose-dependent manner for both cell lines, consistent with reference compound SAHA (<ce:cross-ref id="crosref0240" refid="fig3">Fig. 3</ce:cross-ref>C). These results demonstrated compound <ce:bold>15a</ce:bold> inhibited G1 phase checkpoint through partly up-regulating p21 protein level, which mechanism was similar to reference compound SAHA.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.10" view="all">
                     <ce:label>2.10</ce:label>
                     <ce:section-title id="sectitle0085">Compound <ce:bold>15a</ce:bold> notably induced breast cancer cell apoptosis</ce:section-title>
                     <ce:para id="p0090" view="all">Next, we further confirmed if compound <ce:bold>15a</ce:bold> inhibited tumor cell growth through apoptosis. MDA-MB-231 and 4T1 cells were treated for 72 h with different concentrations of compound <ce:bold>15a</ce:bold>, SAHA and Apigenin were used as reference compounds. Apoptosis was measured by flow cytometry using Annexin V/PI staining. Compared with control, Apigenin, at the concentration of tested of 10 μM, had non-statistically significant apoptotic effect on both tumor cells. Expectantly, SAHA and compound <ce:bold>15a</ce:bold> evidently induced apoptosis in both tumor cells (<ce:cross-ref id="crosref0245" refid="fig4">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor> A and B). Compared with control, compound <ce:bold>15a</ce:bold> prominently increased the percentage of apoptotic cells in response to increasing concentrations. Meanwhile, compound <ce:bold>15a</ce:bold> exhibited more activity in apoptotic induction than SAHA under the same concentration. To further confirm apoptosis induced by compound <ce:bold>15a,</ce:bold> some apoptosis-related proteins, such as p53, Bcl-2, Bax, Caspase-3, and PARP were primordially examined in MDA-MB-231 cells after SAHA and compound <ce:bold>15a</ce:bold> treatments. As shown in <ce:cross-ref id="crosref0250" refid="fig4">Fig. 4</ce:cross-ref>C, treatment with compound <ce:bold>15a</ce:bold> significantly leaded to an increase in the level of cleaved Caspase-3, PARP (biomarkers of cell apoptosis) and a decrease in pro-survival protein Bcl-2 in a dose-dependent manner, but no change was found in p53 or Bax (data not shown). Consistent with apoptosis phenotype, protein changes induced by compound <ce:bold>15a</ce:bold> were seen at concentrations lower than that required for SAHA. Taken together, these data supported compound <ce:bold>15a</ce:bold> could induce tumor cell death via activating apoptosis, which was appeared to be more sensitive in these cell lines than SAHA at higher concentrations that antagonizing activation of STAT3.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.11" view="all">
                     <ce:label>2.11</ce:label>
                     <ce:section-title id="sectitle0210">Preliminary pharmacokinetic (PK) study of compound 15a in rats</ce:section-title>
                     <ce:para id="p0095" view="all">The plasma concentration−time curves for compound <ce:bold>15a</ce:bold> after a single dose in rats were shown in <ce:cross-ref id="crosref0255" refid="fig5">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>. The plasma concentration compound <ce:bold>15a</ce:bold> rapidly reached peak, and remarkably declined after PO administration (PO, <ce:cross-ref id="crosref0260" refid="fig5">Fig. 5</ce:cross-ref>A). The pharmacokinetic of compound <ce:bold>15a</ce:bold> was also investigated by tail intravenous injection (IV, <ce:cross-ref id="crosref0265" refid="fig5">Fig. 5</ce:cross-ref>B). The pharmacokinetic parameters determined with a non-compartmental model were shown in <ce:cross-ref id="crosref0270" refid="tbl5">Table 5</ce:cross-ref>
                        <ce:float-anchor refid="tbl5"/></ce:float-anchor>.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.12" view="all">
                     <ce:label>2.12</ce:label>
                     <ce:section-title id="sectitle0090">Preliminary hERG binding test of compound <ce:bold>15a</ce:bold> 
                        <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0100" view="all">The potency of <ce:bold>15a</ce:bold> for binding the hERG channel was tested by Ice Bioscience Co. Ltd. (China). SAHA and Cisplatin were used as references (shown in <ce:cross-ref id="crosref0275" refid="tbl6">Table 6</ce:cross-ref>
                        <ce:float-anchor refid="tbl6"/></ce:float-anchor>). Both of the listed drugs SAHA and cisplatin demonstrated strong binding effect with hERG channel, which were indicated they had severe heart toxicity. Compound <ce:bold>15a</ce:bold> was shown reduced hERG potency with IC<ce:inf loc="post">50</ce:inf> = 1201 nM.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.13" view="all">
                     <ce:label>2.13</ce:label>
                     <ce:section-title id="sectitle0095">Preliminary Ames test of compound <ce:bold>15a</ce:bold> 
                        <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0105" view="all">To detect the potential mutagenicity of compound <ce:bold>15a</ce:bold>, mini Ames tests were conducted <ce:italic>in vitro</ce:italic>. The Ames tests of compound <ce:bold>15a</ce:bold> and SAHA <ce:italic>in vitro</ce:italic> were achieved by Pharmaron Beijing Co. Ltd. (China). Six wild type bacteria were employed for the tests. As shown in <ce:cross-ref id="crosref0280" refid="tbl7">Table 7</ce:cross-ref>
                        <ce:float-anchor refid="tbl7"/></ce:float-anchor>, SAHA was positive to TA97a and TA100. Similarly, compound <ce:bold>15a</ce:bold> was positive to TA98 and TA100. These results indicated compound <ce:bold>15a</ce:bold> might have some risk to induce mutagenicity. Animal test might be needed for the further validation.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.14" view="all">
                     <ce:label>2.14</ce:label>
                     <ce:section-title id="sectitle0100">Compound <ce:bold>15a</ce:bold> notably suppressed tumor growth <ce:italic>in vivo</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0110" view="all">To evaluate the ability of compound <ce:bold>15a</ce:bold> in inhibiting tumor growth <ce:italic>in vivo</ce:italic>, we examined its effect in xenograft model. In consideration of the uncertain functions of compound <ce:bold>15a</ce:bold> in tumor microenvironment, we firstly assessed the antitumor activity in mice with normal immune system. As shown in <ce:cross-ref id="crosref0285" refid="fig6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor> A and C, p.o (50 mg/kg) and i.p (20 mg/kg) administration of compound <ce:bold>15a</ce:bold> significantly attenuated the growth of implanted 4T1 tumor in Balb/c mice after 22 days of daily administration, in comparison to vehicle treatment group. And the effect between p.o administration and i.p administration was similar. Meanwhile, we also analyzed the antitumor activity of SAHA by daily p.o administration at 150 mg/kg, which was optimal in mice [<ce:cross-ref id="crosref0290" refid="bib8">8</ce:cross-ref>]. As a result, SAHA had no effect in 4T1 model, consistent with previous reports. Next, we assessed the antitumor activity in nude mice without mature T cells. Uniformly, i.p (25 mg/kg) administration visibly blocked the growth of implanted human MDA-MB-231 tumor compared with SAHA (p.o, 150 mg/kg) or vehicle groups, indicating that compound <ce:bold>15a</ce:bold> could kill tumor cells without the help form cytotoxic T lymphocyte (<ce:cross-ref id="crosref0295" refid="fig6">Fig. 6</ce:cross-ref> B and D). In addition, there was no significant decrease of body weight in compound-treated mice, compared to that control group. Collectively, compound <ce:bold>15a</ce:bold> notably inhibited growth of cancer cells <ce:italic>in vivo</ce:italic>, without obvious toxic effect on normal tissues.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.15" view="all">
                     <ce:label>2.15</ce:label>
                     <ce:section-title id="sectitle0105">Compound <ce:bold>15a</ce:bold> inhibited both HDACs and activation of STAT3 <ce:italic>in vivo</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0115" view="all">We have confirmed that compound <ce:bold>15a</ce:bold> could inhibit HDACs and synchronously decrease the level of p-STAT3 upregulated by HDACs inhibition <ce:italic>in vitro</ce:italic>, thereby enhancing its sensitivity to some breast cancer cells. Therefore, we finally examined whether compound <ce:bold>15a</ce:bold> also inhibited both HDACs and STAT3 phosphorylation in xenograft tumor by immunohistochemistry assay. As shown in <ce:cross-ref id="crosref0300" refid="fig7">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>, treatment of compound <ce:bold>15a</ce:bold> resulted in a hyper acetylation of H3 and α-Tubulin in both MDA-MB-231 and 4T1 xenograft model, which compared very favorably to SAHA. Consistent with the data discovered <ce:italic>in vitro</ce:italic>, immunohistochemical staining detected that intratumoral STAT3 phosphorylation was stimulated by SAHA treatment but was effectively reversed by compound <ce:bold>15a</ce:bold> treatment in both xenograft model. Importantly, compound <ce:bold>15a</ce:bold> treatment increased the level of cleaved-Caspase3 implicated in cell death pathways via apoptosis, suggesting more sensitivity to tumor cells than SAHA <ce:italic>in vivo</ce:italic>. These results suggested that in the breast cancer subset where phospho-STAT3 was upregulated by HDAC inhibition, compound <ce:bold>15a</ce:bold> could inhibit both HDACs and p-STAT3 <ce:italic>in vivo</ce:italic> and suppress growth of tumor cells via increasing tumor apoptosis.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0110">Conclusions</ce:section-title>
                  <ce:para id="p0120" view="all">In this study, 28 potential HDACs inhibitors were designed and synthesized based on the structure of flavones and isoflavones. Among them, one lead compound <ce:bold>15a</ce:bold> was discovered and biologically evaluated, which could significantly suppress breast cancer subset growth both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>. Overall, compound <ce:bold>15a</ce:bold> selectively inhibited the activity of HDAC1, HDAC2, HDAC3 (class I) and HDAC6 (class IIB) and induced cell cycle arrest and apoptosis of breast cancer cells. Of note, <ce:bold>15a</ce:bold> antagonized the activation of STAT3 induced by HDACs inhibition, resulting in reducing the level of pro-survive proteins in tumor cells and enhancing anti-tumor activity <ce:italic>in vivo</ce:italic>. In summary, compound <ce:bold>15a</ce:bold> was considered as a novel class of HDACs inhibitors, which merited further validation in the field of chemotherapy of solid tumors.</ce:para>
                  <ce:section id="sec3.1" view="all">
                     <ce:label>3.1</ce:label>
                     <ce:section-title id="sectitle0115">Experimental section</ce:section-title>
                     <ce:section id="sec3.1.1" view="all">
                        <ce:label>3.1.1</ce:label>
                        <ce:section-title id="sectitle0120">General</ce:section-title>
                        <ce:para id="p0125" view="all">All reagents and solvents were purchased from Shanghai Bide Pharmatech Ltd. Co. unless otherwise specified, and used without further purification. Flash column chromatography employed silica gel (100–200 mesh). All compounds were demonstrated to be homogeneous by analytical TLC on precoated silica gel TLC plates (purchased from Qingdao Haiyang Chemical Ltd. Co. 60 F245 on glass, layer thickness 250 μm), and chromatograms were visualized by phosphomolybdic acid staining. Melting points were determined on a micromelting point apparatus. NMR spectra were recorded in CDCl<ce:inf loc="post">3</ce:inf>, unless otherwise stated, on Bruker 400 (<ce:sup loc="post">1</ce:sup> H at 400 MHz, <ce:sup loc="post">13</ce:sup>C at 100 MHz) NMR spectrometers, and chemical shifts are reported in units of <ce:italic>δ</ce:italic> relative to internal TMS. Multiplicities are indicated as br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet), and coupling constants (J) are reported in hertz (Hz). Low and high-resolution mass spectra were performed in The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University. Mass spectral data are reported in the form of <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (intensity relative to base = 100). Purities of the tested compounds were determined by HPLC analysis using Agela Techmolohies HPLC using an Agela Techmolohies MP C18 column (5 μm, 4.6 mm × 50 mm column and Methanol/water) and were >95%. Animals were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.2" view="all">
                        <ce:label>3.1.2</ce:label>
                        <ce:section-title id="sectitle0125">Synthesis of tested compounds</ce:section-title>
                        <ce:para id="p0130" view="all">Ethyl-2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetate (<ce:bold>7a</ce:bold>) To a solution of Chrysin (1.00 g, 3.93 mmol) in DMF (40 mL) was added K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (1.09 g, 7.86 mmol) and compound <ce:bold>6a</ce:bold> (1.31 g, 7.86 mmol) under Ar. The mixture was stirred at 70 °C for 6 h. The mixture was then diluted with EtOAc (200 mL) and washed with saturated NaCl solution (50 mL), dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) to afford compound <ce:bold>7a</ce:bold> (1.08 g, 81%) as a pale yellow solid. M.p. 108.2–109.3 °C; IR (KBr): 3029, 2879, 1723, 1677, 1605, 1340, 1175, 839 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.74 (s, 1H), 7.92–7.83 (m, 2H), 7.59–7.47 (m, 3H), 6.67 (s, 1H), 6.51 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 6.36 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.69 (s, 2H), 4.30 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.32 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.6, 168.0, 164.3, 163.7, 162.5, 132.1, 131.3, 129.2, 126.4, 106.1, 98.6, 93.6, 65.4, 61.9, 14.3. HRMS (ESI) calculated for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">16</ce:inf>NaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 363.0839, found 363.0837.</ce:para>
                        <ce:para id="p0135" view="all">Methyl-4-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butanoate (<ce:bold>7b</ce:bold>) The titled compound <ce:bold>7b</ce:bold> was obtained from Chrysin and <ce:bold>6b</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. It was purified by column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) to afford compound <ce:bold>7b</ce:bold> (80%) as a pale yellow solid. M.p. 118.7–120.3 °C; IR (KBr): 3060, 2953, 1732, 1659, 1613, 1352, 1165, 835 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.69 (s, 1H), 7.86 (dd, <ce:italic>J</ce:italic> = 7.4, 1.9 Hz, 2H), 7.51 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 3H), 6.64 (s, 1H), 6.47 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.33 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 3.70 (s, 3H), 2.54 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 2.15 (t, <ce:italic>J</ce:italic> = 6.7 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.6, 173.5, 164.9, 164.1, 162.3, 157.9, 132.0, 131.4, 129.2, 126.4, 106.0, 98.8, 93.2, 67.5, 51.9, 30.5, 24.5. HRMS (ESI) calculated for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">18</ce:inf>NaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 377.0996, found 377.0993.</ce:para>
                        <ce:para id="p0140" view="all">Methyl 5-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy) pentanoate (<ce:bold>7c</ce:bold>) The titled compound <ce:bold>7c</ce:bold> was obtained from Chrysin and <ce:bold>6c</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7c</ce:bold> (83%) as a pale yellow solid. M.p. 98.5–99.9 °C; IR (KBr): 3077, 2927, 1735, 1659, 1353, 1176, 820 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.70 (s, 1H), 7.88 (dt, <ce:italic>J</ce:italic> = 8.1, 1.4 Hz, 2H), 7.53 (dt, <ce:italic>J</ce:italic> = 5.8, 2.9 Hz, 3H), 6.66 (s, 1H), 6.49 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 6.35 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.05 (q, <ce:italic>J</ce:italic> = 4.5, 3.2 Hz, 2H), 3.68 (d, <ce:italic>J</ce:italic> = 2.9 Hz, 3H), 2.42 (t, <ce:italic>J</ce:italic> = 6.9 Hz, 2H), 1.85 (dtt, <ce:italic>J</ce:italic> = 6.7, 4.9, 2.4 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.5, 165.0, 164.0, 162.2, 131.8, 131.4, 129.1, 126.3, 105.9, 98.6, 93.1, 68.1, 51.6, 33.6, 28.4, 21.5. HRMS (ESI) calculated for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">20</ce:inf>NaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 391.1152, found 391.1153.</ce:para>
                        <ce:para id="p0145" view="all">Methyl-6-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>7d</ce:bold>) The titled compound <ce:bold>7d</ce:bold> was obtained from Chrysin and <ce:bold>6d</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7d</ce:bold> (86%) as a pale yellow solid. M.p. 117.8–118.3 °C; IR (KBr): 2922, 2852, 1727, 1656, 1355, 1167, 834 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.70 (s, 1H), 7.94–7.84 (m, 2H), 7.52 (q, <ce:italic>J</ce:italic> = 6.5 Hz, 3H), 6.66 (s, 1H), 6.48 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.35 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.03 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.68 (s, 3H), 2.36 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.84 (p, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 1.73 (q, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.58–1.47 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.6, 174.1, 165.2, 164.1, 162.3, 157.9, 131.9, 131.5, 129.2, 126.4, 106.0, 98.7, 93.2, 68.5, 51.7, 34.1, 28.8, 25.7, 24.7. HRMS (ESI) calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">22</ce:inf>NaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 405.1309, found 405.1308.</ce:para>
                        <ce:para id="p0150" view="all">Ethyl-7-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)heptanoate (<ce:bold>7e</ce:bold>) The titled compound <ce:bold>7e</ce:bold> was obtained from Chrysin and <ce:bold>6e</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7e</ce:bold> (82%) as a pale yellow solid. M.p. 95.6–96.8 °C; IR (KBr): 3056, 2975, 1736, 1658, 1349, 1174, 832 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.69 (s, 1H), 8.15–7.74 (m, 2H), 7.52 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 3H), 6.65 (s, 1H), 6.48 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.34 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.13 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 4.02 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 2.32 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.82 (p, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 1.67 (dd, <ce:italic>J</ce:italic> = 8.8, 6.0 Hz, 2H), 1.45 (dq, <ce:italic>J</ce:italic> = 28.2, 7.6 Hz, 4H), 1.25 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.6, 165.3, 164.0, 162.3, 157.9, 131.9, 131.5, 129.2, 126.4, 106.0, 98.7, 93.2, 68.6, 60.4, 34.4, 28.92, 28.9, 25.8, 25.0, 14.4. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>NaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 433.1622, found 433.1625.</ce:para>
                        <ce:para id="p0155" view="all">Methyl-8-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)octanoate (<ce:bold>7f</ce:bold>) The titled compound <ce:bold>7f</ce:bold> was obtained from Chrysin and <ce:bold>6f</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7f</ce:bold> (86%) as a pale yellow solid. M.p. 95.9–97.0 °C. IR (KBr): 3011, 2957, 1751, 1637, 1342, 1165, 852 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.66 (s, 1H), 8.04–7.77 (m, 2H), 7.65–7.40 (m, 3H), 6.61 (s, 1H), 6.44 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.31 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 3.98 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.65 (s, 3H), 2.30 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.82–1.73 (m, 2H), 1.63 (p, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.49–1.42 (m, 2H), 1.40–1.31 (m, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 165.2, 163.9, 162.1, 157.8, 131.8, 131.3, 129.1, 126.3, 105.8, 98.7, 93.1, 68.7, 51.5, 34.1, 29.1, 29.0, 28.9, 25.8, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>NaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 433.1622, found 433.1624.</ce:para>
                        <ce:para id="p0160" view="all">Methyl-6-((5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>7g</ce:bold>) The titled compound <ce:bold>7g</ce:bold> was obtained from Acacetin and <ce:bold>6d</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7g</ce:bold> (89%) as a white solid. M.p. 102.7–104.2 °C; IR (KBr): 2931, 2852, 1644, 1609, 1239, 1178, 839 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.75 (d, <ce:italic>J</ce:italic> = 1.3 Hz, 1H), 7.84–7.67 (m, 2H), 7.01–6.84 (m, 2H), 6.49 (d, <ce:italic>J</ce:italic> = 1.3 Hz, 1H), 6.39 (t, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 6.27 (t, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 3.97 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.84 (d, <ce:italic>J</ce:italic> = 1.4 Hz, 3H), 3.66 (d, <ce:italic>J</ce:italic> = 1.3 Hz, 3H), 2.34 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.80 (p, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.69 (p, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.49 (h, <ce:italic>J</ce:italic> = 7.0, 6.5 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 174.0, 164.9, 163.9, 162.6, 162.1, 157.6, 128.0, 123.5, 114.5, 105.4, 104.2, 98.5, 92.9, 68.3, 55.5, 51.6, 34.0, 28.7, 25.6, 24.7. HRMS (ESI) calculated for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">24</ce:inf>NaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 435.1414, found 435.1413.</ce:para>
                        <ce:para id="p0165" view="all">Ethyl-7-((5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)heptanoate (<ce:bold>7h</ce:bold>) The titled compound <ce:bold>7h</ce:bold> was obtained from Acacetin and <ce:bold>6e</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7h</ce:bold> (84%) as a white solid. M.p. 93.4–94.7 °C; IR (KBr): 2982, 2834, 1659, 1611, 1258, 1168, 835 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.76 (s, 1H), 7.88–7.75 (m, 2H), 7.04–6.93 (m, 2H), 6.54 (s, 1H), 6.44 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.12 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 4.00 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.87 (s, 3H), 2.31 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.87–1.75 (m, 2H), 1.67 (p, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.48 (q, <ce:italic>J</ce:italic> = 7.6, 7.1 Hz, 2H), 1.44–1.33 (m, 2H), 1.25 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 3H).<ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.49, 168.92 (d, <ce:italic>J</ce:italic> = 983.6 Hz), 165.1, 162.7, 162.2, 157.8, 128.1, 123.7, 114.6, 104.4, 98.6, 93.1, 68.6, 60.4, 55.6, 34.4, 28.9, 25.8, 25.0, 14.4. HRMS (ESI) calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 463.1727, found 463.1725.</ce:para>
                        <ce:para id="p0170" view="all">Methyl-8-((5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)octanoate (<ce:bold>7i</ce:bold>) The titled compound <ce:bold>7i</ce:bold> was obtained from Acacetin and <ce:bold>6f</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7i</ce:bold> (87%) as a white solid. M.p. 106.1–107.3 °C; IR (KBr): 2894, 2833, 1639, 1615, 1189, 841 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.80 (s, 1H), 7.88–7.80 (m, 2H), 7.06–6.97 (m, 2H), 6.57 (s, 1H), 6.47 (d, <ce:italic>J</ce:italic> = 2.4 Hz, 1H), 6.34 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.02 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.89 (s, 3H), 3.68 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 3H), 2.33 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.81 (p, <ce:italic>J</ce:italic> = 6.9 Hz, 2H), 1.65 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.47 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 1.43–1.33 (m, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 174.3, 165.0, 164.0, 162.1, 157.7, 128.0, 123.6, 114.48, 105.4, 104.3, 98.4, 93.0, 68.6, 55.6, 51.5, 34.1, 29.0, 29.0, 28.9, 25.8, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">28</ce:inf>NaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+,</ce:sup>463.1727, found 463.1729.</ce:para>
                        <ce:para id="p0175" view="all">Methyl-6-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>7j</ce:bold>) The titled compound <ce:bold>7j</ce:bold> was obtained from Apigenin and <ce:bold>6d</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7j</ce:bold> (33%) as a pale yellow solid. M.p. 175.4–176.7 °C; IR (KBr): 3079, 3006, 2943, 1731, 1655, 1605, 1175, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.94 (s, 1H), 10.38 (s, 1H), 7.95 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.93 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.83 (s, 1H), 6.75 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.34 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.59 (s, 3H), 2.34 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.74 (p, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.59 (q, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.43 (q, <ce:italic>J</ce:italic> = 8.3 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.3, 173.7, 165.0, 164.5, 161.8, 161.6, 157.7, 129.0, 121.5, 116.4, 105.1, 103.5, 98.7, 93.5, 68.7, 51.6, 33.7, 28.5, 25.4, 24.6. HRMS (ESI) calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">22</ce:inf>NaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup>421.1258, found 421.1259.</ce:para>
                        <ce:para id="p0180" view="all">Ethyl-7-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)heptanoate (<ce:bold>7k</ce:bold>) The titled compound <ce:bold>7k</ce:bold> was obtained from Apigenin and <ce:bold>6e</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7k</ce:bold> (30%) as a pale yellow solid. M.p. 109.1–110.2 °C; IR (KBr): 3061, 2981, 2940, 1739, 1658, 1617, 1501, 1169, 832 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.94 (s, 1H), 10.48 (s, 1H), 7.95 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.96 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.83 (s, 1H), 6.75 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.34 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.06 (p, <ce:italic>J</ce:italic> = 6.7 Hz, 4H), 3.34 (s, 3H), 2.29 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.73 (p, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 1.55 (p, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.37 (ddt, <ce:italic>J</ce:italic> = 24.5, 14.5, 6.8 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.8, 172.8, 164.5, 161.4, 161.1, 157.2, 128.5, 121.0, 116.0, 103.0, 98.2, 93.0, 68.3, 59.6, 33.4, 28.2, 28.1, 25.01, 24.3, 14.1. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>NaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 449.1571 found 449.1573.</ce:para>
                        <ce:para id="p0185" view="all">Methyl-8-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)octanoate (<ce:bold>7l</ce:bold>) The titled compound <ce:bold>7l</ce:bold> was obtained from Apigenin and <ce:bold>6f</ce:bold> following the general procedure described for <ce:bold>7a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) afforded compound <ce:bold>7l</ce:bold> (29%) as a pale yellow solid. M.p. 126.6–127.8 °C; IR (KBr): 3272, 2853, 1737, 1162, 1587, 1498, 1376, 1178, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.94 (s, 1H), 10.52 (s, 1H), 7.95 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 6.95 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 2H), 6.83 (d, <ce:italic>J</ce:italic> = 4.0 Hz, 1H), 6.76 (s, 1H), 6.34 (t, <ce:italic>J</ce:italic> = 3.4 Hz, 1H), 4.09 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.58 (t, <ce:italic>J</ce:italic> = 3.1 Hz, 3H), 2.30 (t, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.73 (s, 2H), 1.60–1.47 (m, 2H), 1.36 (d, <ce:italic>J</ce:italic> = 37.3 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.8, 173.3, 164.5, 164.0, 161.4, 161.1, 157.2, 128.4, 120.9, 116.0, 104.5, 102.9, 98.3, 93.0, 68.4, 51.1, 33.2, 28.3, 28.2, 25.1, 24.3. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>NaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 449.1571, found 449.1574.</ce:para>
                        <ce:para id="p0190" view="all">N-Hydroxy-2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetamide (<ce:bold>8a</ce:bold>) To a solution of Hydroxylamine hydrochloride (614 mg, 8.84 mmol) in CH<ce:inf loc="post">3</ce:inf>OH (5 mL) was added KOH (744 mg, 13.3 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 h and white solid was formed. The residue was then filtered and afforded hydroxylamine in CH<ce:inf loc="post">3</ce:inf>OH solution. Compound <ce:bold>7a</ce:bold> (136 mg, 0.400 mmol) was dissolved in CH<ce:inf loc="post">3</ce:inf>OH (obtained above, 4 mL) at 0 °C and stirred at RT for 1 h. Then yellow solid was formed. The residue was filtered and washed with CH<ce:inf loc="post">3</ce:inf>OH to afford compound <ce:bold>8a</ce:bold> (124 mg, 95%) as a yellow solid. M.p. 236.8–238.2 °C; IR (KBr): 3072, 3003, 2919, 1664, 1612, 1452, 1364, 1178, 836 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.82 (s, 1H), 11.00 (s, 1H), 10.12 (s, 1H), 8.15–8.05 (m, 2H), 7.69–7.56 (m, 3H), 7.06 (s, 1H), 6.83 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.45 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.64 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.0, 163.67, 163.6, 163.5, 161.1, 157.1, 132.1, 130.5, 129.1, 126.4, 105.4, 105.3, 98.7, 93.5, 66.1. HRMS (ESI) calculated for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">13</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 350.0635, found 350.0636.</ce:para>
                        <ce:para id="p0195" view="all">N-Hydroxy-4-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butanamide (<ce:bold>8b</ce:bold>) The titled compound <ce:bold>8b</ce:bold> was obtained from <ce:bold>7b</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. The compound <ce:bold>8b</ce:bold> (93%) was a yellow solid. M.p. 153.9–155.5 °C; IR (KBr): 3045, 2937, 1664, 1609, 1507, 1233, 1179, 838 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.79 (s, 1H), 10.46 (s, 1H), 8.76 (s, 1H), 8.08 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.60 (dd, <ce:italic>J</ce:italic> = 11.3, 7.1 Hz, 3H), 7.02 (s, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.36 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.14 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.96 (t, <ce:italic>J</ce:italic> = 6.9 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.1, 168.5, 164.6, 163.4, 161.2, 157.4, 132.2, 130.6, 129.2, 126.5, 105.3, 98.6, 93.2, 67.9, 28.6, 24.5. HRMS (ESI) calculated for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">17</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 378.0948, found 378.0948.</ce:para>
                        <ce:para id="p0200" view="all">N-Hydroxy-5-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)pentanamide (<ce:bold>8c</ce:bold>) The titled compound <ce:bold>8c</ce:bold> was obtained from <ce:bold>7c</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. The compound <ce:bold>8c</ce:bold> (91%) was a yellow solid. M.p. 190.6–192.5 °C; IR (KBr): 3217, 2926, 1641, 1609, 1503, 1353, 1168, 829 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.78 (s, 1H), 10.44 (s, 1H), 10.09 (s, 1H), 8.09 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 7.67–7.52 (m, 3H), 7.02 (s, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.37 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.09 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 2.04 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.68 (dq, <ce:italic>J</ce:italic> = 26.1, 7.1 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.1, 168.9, 164.7, 163.5, 161.2, 132.2, 130.6, 129.2, 126.5, 105.3, 104.9, 98.5, 93.2, 68.2, 31.8, 27.9, 21.7. HRMS (ESI) calculated for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">19</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 392.1105, found 392.1107.</ce:para>
                        <ce:para id="p0205" view="all">N-Hydroxy-6-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)hexanamide (<ce:bold>8d</ce:bold>) The titled compound <ce:bold>8d</ce:bold> was obtained from <ce:bold>7d</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. The compound <ce:bold>8d</ce:bold> (90%) was a yellow solid. M.p. 158.2–160.1 °C; IR (KBr): 3019, 12933, 1633, 1654, 1514, 1178, 842 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.80 (s, 1H), 10.38 (s, 1H), 8.71 (s, 1H), 8.10 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.61 (dd, <ce:italic>J</ce:italic> = 10.9, 7.1 Hz, 3H), 7.04 (s, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.37 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 1.98 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.73 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.55 (q, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.39 (q, <ce:italic>J</ce:italic> = 8.0 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 182.1, 169.0, 164.7, 163.4, 161.2, 157.4, 132.2, 130.6, 129.2, 126.5, 105.3, 104.9, 98.5, 93.1, 68.4, 32.2, 28.2, 25.1, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">21</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 406.1261, found 406.12610.</ce:para>
                        <ce:para id="p0210" view="all">N-Hydroxy-7-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)heptanamide (<ce:bold>8e</ce:bold>) The titled compound <ce:bold>8e</ce:bold> was obtained from <ce:bold>7e</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold> as a yellow solid (96%). M.p. 158.9–160.0 °C; IR (KBr): 3077, 2984, 1644, 1631, 1351, 1169, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.77 (s, 1H), 10.36 (s, 1H), 8.69 (s, 1H), 8.07 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.78–7.34 (m, 3H), 7.00 (s, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.34 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.05 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 1.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.71 (p, <ce:italic>J</ce:italic> = 7.4, 7.0 Hz, 2H), 1.51 (p, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.39 (p, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 1.30 (q, <ce:italic>J</ce:italic> = 7.5 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.0, 169.1, 164.8, 163.4, 161.2, 157.37, 132.2, 130.6, 129.2, 126.5, 105.3, 104.9, 98.5, 93.2, 68.5, 32.2, 28.3, 25.1, 25.1. HRMS (ESI) calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">23</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 420.1418, found 420.1415.</ce:para>
                        <ce:para id="p0215" view="all">N-Hydroxy-8-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)octanamide (<ce:bold>8f</ce:bold>) The titled compound <ce:bold>8f</ce:bold> was obtained from <ce:bold>7f</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold> as a yellow solid (93%). M.p. 134.7–136.1 °C; IR (KBr): 3069, 2937, 1753, 1647, 1362, 1172, 836 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.77 (s, 1H), 10.36 (s, 1H), 8.68 (s, 1H), 8.07 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 7.58 (dt, <ce:italic>J</ce:italic> = 14.4, 6.9 Hz, 3H), 7.00 (s, 1H), 6.54 (dd, <ce:italic>J</ce:italic> = 167.1, 2.2 Hz, 2H), 4.04 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 1.95 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.70 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.50 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.45–1.18 (m, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.0, 169.1, 164.7, 163.4, 161.1, 157.3, 132.1, 130.6, 129.1, 126.4, 105.3, 98.4, 93.1, 68.5, 32.3, 28.5, 28.4, 28.4, 25.2, 25.1. HRMS (ESI) calculated for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">26</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 434.1574, found 434.1571.</ce:para>
                        <ce:para id="p0220" view="all">N-Hydroxy-6-((5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanamide (<ce:bold>8g</ce:bold>) The titled compound <ce:bold>8g</ce:bold> was obtained from <ce:bold>7g</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 10:1) to afford compound <ce:bold>8g</ce:bold> (95%) as a white solid. M.p. 129.3–130.5 °C; IR (KBr): 3051, 2798, 1688, 1631, 1189, 835 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.16–7.91 (m, 2H), 7.22–7.01 (m, 2H), 6.90 (d, <ce:italic>J</ce:italic> = 3.8 Hz, 1H), 6.73 (s, 1H), 6.31 (s, 1H), 4.07 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.96–3.76 (m, 3H), 1.95 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.72 (s, 2H), 1.50 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.40 (s, 2H), 1.30 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.8, 168.8, 164.5, 163.4, 157.4, 128.4, 122.8, 114.6, 104.8, 103.8, 98.45, 92.8, 68.3, 55.6, 32.3, 28.2, 25.1, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">23</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 436.1367, found 436.1369.</ce:para>
                        <ce:para id="p0225" view="all">N-hydroxy-7-((5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)heptanamide (<ce:bold>8h</ce:bold>) The titled compound <ce:bold>8h</ce:bold> was obtained from <ce:bold>7h</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 10:1) to afford compound <ce:bold>8h</ce:bold> (96%) as a white solid. M.p. 141.6–143.3 °C; IR (KBr): 3011, 2952, 1639, 1619, 1188, 839 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.17–8.01 (m, 2H), 7.23–7.09 (m, 2H), 6.91 (d, <ce:italic>J</ce:italic> = 3.8 Hz, 1H), 6.74 (s, 1H), 6.33 (s, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.97–3.79 (m, 3H), 1.96 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.74 (s, 2H), 1.52 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.41 (s, 2H), 1.31 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.2, 169.4, 165.0, 163.8, 162.8, 128.8, 123.2, 115.1, 104.3, 100.0, 100.0, 68.8, 56.1, 49.1, 32.7, 28.8, 25.6, 25.6. HRMS (ESI) calculated for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 450.1523, found 450.1525.</ce:para>
                        <ce:para id="p0230" view="all">N-Hydroxy-8-((5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)octanamide (<ce:bold>8i</ce:bold>) The titled compound <ce:bold>8i</ce:bold> was obtained from <ce:bold>7i</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 10:1) to afford compound <ce:bold>8i</ce:bold> (92%) as a white solid. M.p. 133.9–135.7 °C; IR (KBr): 3249, 2934, 1654, 1610, 1169, 843 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.09–7.99 (m, 2H), 7.18–7.08 (m, 2H), 6.85 (s, 1H), 6.65 (s, 1H), 6.26 (d, <ce:italic>J</ce:italic> = 2.5 Hz, 1H), 4.05 (t, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 3.86 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 3H), 1.94 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.72 (p, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.50 (p, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.39 (q, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.35–1.24 (m, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.0, 169.2, 164.9, 162.7, 157.9, 128.7, 123.3, 115.0, 104.3, 99.0, 92.8, 68.7, 56.0, 32.8, 29.0, 28.9, 28.9, 28.8, 25.8, 25.6. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">27</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 464.1680, found 464.1681.</ce:para>
                        <ce:para id="p0235" view="all">N-Hydroxy-6-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanamide (<ce:bold>8j</ce:bold>) The titled compound <ce:bold>8j</ce:bold> was obtained from <ce:bold>7j</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. It was purified by chromatography on silica gel (CH2Cl2: CH3OH = 10:1) to afford compound 8j (93%) as a yellow solid. M.p. 121.3–122.5 °C; IR (KBr): 3167, 2931, 1657,1599, 1503, 1444, 1170, 841 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.95 (s, 1H), 10.49 (s, 1H), 10.39 (s, 1H), 8.70 (s, 1H), 7.96 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.95 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 6.86 (s, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.35 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 1.98 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.73 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.56 (p, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.39 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 169.1, 164.5, 164.1, 161.6, 161.2, 157.3, 128.5, 120.9, 116.1, 104.6, 102.9, 98.3, 93.1, 68.4, 32.2, 28.2, 25.1, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">21</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 422.1210, found 422.1209.</ce:para>
                        <ce:para id="p0240" view="all">N-hydroxy-7-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)heptanamide (<ce:bold>8k</ce:bold>) The titled compound <ce:bold>8k</ce:bold> was obtained from <ce:bold>7k</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 10:1) to afford compound <ce:bold>8k</ce:bold> (96%) as a yellow solid. M.p. 113.5–115.0 °C; IR (KBr): 3061, 2982, 1739, 1658, 1607, 1353, 1116, 846 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.95 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 10.68 (s, 1H), 10.49 (s, 1H), 8.71 (s, 1H), 8.03–7.85 (m, 2H), 7.09–6.94 (m, 2H), 6.84 (dd, <ce:italic>J</ce:italic> = 3.9, 2.1 Hz, 1H), 6.77 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.35 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 2.00 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.74 (p, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.56 (q, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.39 (dd, <ce:italic>J</ce:italic> = 15.1, 7.6 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 169.1, 164.5, 164.1, 161.5, 161.1, 157.2, 128.5, 120.9, 116.0, 104.6, 102.9, 98.3, 93.0, 68.4, 32.2, 28.5, 28.4, 28.3, 25.3, 25.3. HRMS (ESI) calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">23</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 436.1367, found 436.1368.</ce:para>
                        <ce:para id="p0245" view="all">N-Hydroxy-8-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)octanamide (<ce:bold>8l</ce:bold>) The titled compound <ce:bold>8l</ce:bold> was obtained from <ce:bold>7l</ce:bold> following the general procedure described for <ce:bold>8a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 10:1) to afford compound <ce:bold>8l</ce:bold> (94%) as a yellow solid. M.p. 132.5–134.2 °C; IR (KBr): 3166, 2944, 1657, 1660, 1502, 1443, 1254, 1170, 836 cm <ce:sup loc="post">−1</ce:sup>.<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.95 (s, 1H), 10.45 (s, 1H), 10.37 (s, 1H), 8.68 (s, 1H), 7.97 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 6.94 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 6.86 (s, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.36 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.08 (s, 2H), 1.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.72 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.52 (p, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.40 (q, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.36–1.26 (m, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.8, 164.5, 164.1, 161.5, 161.1, 157.2, 128.4, 120.8, 116.0, 102.9, 98.3, 93.0, 68.4, 32.2, 31.1, 29.8, 29.0, 28.2, 25.1, 25.0. HRMS (ESI) calculated for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 450.1523, found 450.1525.</ce:para>
                        <ce:para id="p0250" view="all">6-((3-(4-Methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-N-((tetrahydro-2H-pyran-2-yl)oxy)hexanamide(<ce:bold>10a</ce:bold>) To a solution of 6-Bromohexanoic acid (1.39 mL, 10.0 mmol) and O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine (1.17 g, 10.0 mmol) in CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (100 mL) were added HOBT (1.62 g, 12.0 mmol), EDCI (2.30 g, 12.0 mmol) and DIPEA (12 mL, 72.6 mmol) successively at 0 °C. The mixture was stirred at RT overnight. The mixture was then washed with saturated NaHCO<ce:inf loc="post">3</ce:inf> solution (50 mL) and saturated NaCl solution (50 mL), dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and concentrated under reduced pressure to afford compound <ce:bold>9a</ce:bold> as thick oil, which was used directly in the next step without further purification. To a solution of compound <ce:bold>9a</ce:bold> (obtained above) and compound Formononetin (1.79 g, 6.67 mmol) in DMF (67 mL) was added K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (1.84 g, 13.3 mmol) under Ar. The mixture was stirred at 70 °C for 6 h. Then the mixture was diluted with EtOAc (200 mL) and washed with saturated NaCl solution (50 mL), dried over Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 90:1) to afford compound <ce:bold>10a</ce:bold> (2.74 g, 61% for two steps) as a white solid. M.p. 103.2–104.3 °C; IR (KBr): 2944, 2869, 1632, 1513, 1251, 1179, 1027, 828 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.12 (s, 1H), 8.17 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.90 (s, 1H), 7.55–7.41 (m, 2H), 7.01–6.90 (m, 3H), 6.80 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.96 (s, 1H), 4.01 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 3.83 (s, 3H), 2.14 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.79 (ddd, <ce:italic>J</ce:italic> = 32.2, 15.0, 6.8 Hz, 8H), 1.57 (qt, <ce:italic>J</ce:italic> = 15.6, 6.5 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 175.9, 163.4, 159.5, 157.9, 152.1, 130.1, 127.6, 124.8, 124.2, 118.2, 114. 9, 113.9, 102.4, 100.5, 68.4, 62.4, 55.3, 33.0, 28.7, 28.0, 25.6, 25.0, 18.6. HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">31</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 504.1993, found 504.1992.</ce:para>
                        <ce:para id="p0255" view="all">7-((3-(4-Methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-N-((tetrahydro-2H-pyran-2-yl)oxy)heptanamide (<ce:bold>10b</ce:bold>) The titled compound <ce:bold>10b</ce:bold> was obtained from Formononetin following the general procedure described for <ce:bold>10a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>10b</ce:bold> (65%) as a white solid. M.p. 92.6–93.7 °C; IR (KBr): 3140, 2942, 1639, 1513, 1145, 1252, 1111, 1033, 821 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.40 (s, 1H), 8.12 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.84 (s, 1H), 7.49–7.37 (m, 2H), 6.89 (dd, <ce:italic>J</ce:italic> = 8.9, 2.1 Hz, 3H), 6.75 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.88 (s, 1H), 3.96 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.86 (d, <ce:italic>J</ce:italic> = 10.2 Hz, 1H), 3.77 (s, 3H), 3.62–3.50 (m, 1H), 2.05 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 1.74 (dt, <ce:italic>J</ce:italic> = 14.8, 8.6 Hz, 5H), 1.64 (p, <ce:italic>J</ce:italic> = 7.2 Hz, 3H), 1.57–1.30 (m, 7H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 176.0, 170.5, 163.5, 159.5, 158.0, 152.1, 130.1, 127.7, 124.8, 124.2, 118.2, 114.9, 113.9, 102.5, 100.5, 68.5, 62.5, 55.3, 33.2, 28.8, 28.0, 25.7, 25.0, 18.6. HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">33</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 518.2149, found 518.2148.</ce:para>
                        <ce:para id="p0260" view="all">8-((3-(4-Methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-N-((tetrahydro-2H-pyran-2-yl)oxy)octanamide (<ce:bold>10c</ce:bold>) The titled compound <ce:bold>10c</ce:bold> was obtained from Formononetin following the general procedure described for <ce:bold>10a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>10c</ce:bold> (64%) as a white solid. M.p. 98.0–99.4 °C; IR (KBr): 3191, 2929, 1632, 1514, 1446, 1250, 1112, 827 cm <ce:sup loc="post">−1</ce:sup>.<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.40 (s, 1H), 8.20 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.92 (s, 1H), 7.55–7.45 (m, 2H), 6.97 (dd, <ce:italic>J</ce:italic> = 8.8, 2.1 Hz, 3H), 6.83 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.95 (s, 1H), 4.04 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.93 (d, <ce:italic>J</ce:italic> = 10.8 Hz, 1H), 3.84 (s, 3H), 3.63 (ddt, <ce:italic>J</ce:italic> = 9.6, 5.5, 2.9 Hz, 1H), 2.11 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 2H), 1.83 (p, <ce:italic>J</ce:italic> = 6.5 Hz, 4H), 1.73–1.53 (m, 6H), 1.48 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 1.42–1.34 (m, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.1, 174.0, 169.7, 168.8, 166.9, 166.4, 162.5, 133.6, 127.8, 120.2, 109.9, 108.8, 103.6, 100.0, 98.3, 73.3, 71.4, 62.8, 50.8, 37.0, 33.1, 26.9. HRMS (ESI) calculated for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">35</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 532.2306, found 532.2306.</ce:para>
                        <ce:para id="p0265" view="all">6-((5-Hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-N-((tetrahydro-2H-pyran-2-yl)oxy)hexanamide (<ce:bold>10d</ce:bold>) The titled compound <ce:bold>10d</ce:bold> was obtained from Formononetin following the general procedure described for <ce:bold>10a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>10d</ce:bold> (67%) as a white solid. M.p. 108.3–110.1 °C; IR (KBr): 3210, 2943, 1672, 1459, 1421, 1231, 1179, 1029, 821 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.82 (s, 1H), 8.64 (s, 1H), 7.84 (s, 1H), 7.48–7.38 (m, 2H), 7.03–6.91 (m, 2H), 6.39–6.27 (m, 2H), 4.94 (s, 1H), 3.99 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 3.83 (s, 3H), 2.14 (s, 2H), 1.77 (dq, <ce:italic>J</ce:italic> = 25.1, 7.6 Hz, 8H), 1.64–1.44 (m, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 165.1, 162.7, 159.9, 158.0, 152.8, 130.2, 123.7, 114.18, 102.6, 98.7, 92.87, 68.4, 62.7, 55.5, 33.2, 28.8, 28.1, 25.7, 25.09, 18.7. HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">31</ce:inf>NNaO<ce:inf loc="post">8</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 520.1942, found 520.1945.</ce:para>
                        <ce:para id="p0270" view="all">7-((5-Hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-N-((tetrahydro-2H-pyran-2-yl)oxy)heptanamide (<ce:bold>10e</ce:bold>) The titled compound <ce:bold>10e</ce:bold> was obtained from dihydroxyl-4′-methoxyisoflavone following the general procedure described for <ce:bold>10a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>10e</ce:bold> (62%) as a white solid. M.p. 115.3–116.2 °C; IR (KBr): 3161, 2953, 1663, 1467, 1413, 1249, 1183, 1035, 839 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.83 (s, 1H), 8.45 (s, 1H), 7.85 (s, 1H), 7.51–7.40 (m, 2H), 7.03–6.89 (m, 2H), 6.42–6.30 (m, 2H), 4.94 (s, 1H), 4.00 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.83 (s, 3H), 2.12 (s, 2H), 1.85–1.56 (m, 12H), 1.45 (dt, <ce:italic>J</ce:italic> = 23.5, 7.5 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 180.8, 165.1, 162.6, 159.8, 157.9, 152.7, 130.1, 123.6, 123.0, 114.1, 103.1(d, <ce:italic>J</ce:italic> = 620.0 Hz), 98.6, 92.8, 68.5, 62.6, 55.4, 28.8, 28.7, 28.0, 25.7, 25.0. HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">33</ce:inf>NNaO<ce:inf loc="post">8</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 534.2098, found 534.2095.</ce:para>
                        <ce:para id="p0275" view="all">7-((5-Hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)-N-((tetrahydro-2H-pyran-2-yl)oxy)heptanamide (<ce:bold>10f</ce:bold>) The titled compound <ce:bold>10f</ce:bold> was obtained from dihydroxyl-4′-methoxyisoflavone following the general procedure described for <ce:bold>10a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>10f</ce:bold> (64%) as a white solid. M.p. 124.9–126.7 °C; IR (KBr): 2944, 2853, 1658, 1516, 1246, 1135, 836 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.85 (s, 1H), 8.27 (s, 1H), 7.86 (s, 1H), 7.49–7.44 (m, 2H), 7.02–6.94 (m, 2H), 6.41–6.33 (m, 2H), 4.95 (s, 1H), 4.01 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.93 (d, <ce:italic>J</ce:italic> = 10.4 Hz, 1H), 3.85 (s, 3H), 3.64 (ddd, <ce:italic>J</ce:italic> = 11.0, 5.6, 3.9 Hz, 1H), 2.12 (s, 2H), 1.85–1.78 (m, 4H), 1.71–1.56 (m, 6H), 1.46 (s, 2H), 1.39 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 180.9, 165.2, 162.8, 159.9, 158.1, 152.8, 130.2, 123.1, 114.2, 102.7, 98.7, 93.0, 68.7, 62.7, 55.5, 33.45, 29.2, 29.1, 29.0, 28.1, 25.9, 25.1, 18.7. HRMS (ESI) calculated for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">35</ce:inf>NNaO<ce:inf loc="post">8</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 548.2255, found 548.2253.</ce:para>
                        <ce:para id="p0280" view="all">N-Hydroxy-6-((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanamide (<ce:bold>11a</ce:bold>) To a solution of compound <ce:bold>10a</ce:bold> (1.00 g, 2.07 mmol) in anhydrous CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (2 mL) was added 1 M HCl/Et<ce:inf loc="post">2</ce:inf>O solution (20 mL, 20.0 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>11a</ce:bold> (68%) as a white solid. M.p. 123.5–125.1 °C; IR (KBr): 2939, 2869, 1632, 1513, 1445, 1250, 1179, 828 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.41 (s, 1H), 8.72 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 8.42 (s, 1H), 8.02 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.59–7.48 (m, 2H), 7.15 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.07 (dd, <ce:italic>J</ce:italic> = 8.9, 2.3 Hz, 1H), 7.04–6.95 (m, 2H), 4.11 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.79 (s, 3H), 2.00 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.76 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.63–1.54 (m, 2H), 1.42 (td, <ce:italic>J</ce:italic> = 8.6, 4.4 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 174.6, 169.0, 163.1, 159.0, 157.5, 153.5, 130.1, 126.9, 124.1, 117.5, 115.1, 113.6, 101.0, 68.4, 55.2, 32.2, 28.2, 25.1, 24.9. HRMS (ESI) calculated for C22H23NNaO6<ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 420.1418, found 420.1417.</ce:para>
                        <ce:para id="p0285" view="all">N-Hydroxy-7-((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)heptanamide (<ce:bold>11b</ce:bold>) The titled compound <ce:bold>11b</ce:bold> was obtained from <ce:bold>10b</ce:bold> following the general procedure described for <ce:bold>11a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>11b</ce:bold> (64%) as a white solid. M.p. 128.1–130.0 °C; IR (KBr): 2927, 2857, 1632, 1514, 1178, 1027, 828 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.41 (s, 1H), 8.71 (s, 1H), 8.43 (s, 1H), 8.02 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.60–7.43 (m, 2H), 7.15 (d, <ce:italic>J</ce:italic> = 2.4 Hz, 1H), 7.08 (dd, <ce:italic>J</ce:italic> = 8.9, 2.3 Hz, 1H), 7.04–6.94 (m, 2H), 4.11 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.79 (s, 3H), 1.97 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.75 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.52 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.43 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.32 (q, <ce:italic>J</ce:italic> = 8.1 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 174.7, 163.1, 159.0, 157.5, 153.5, 130.1, 126.9, 124.1, 123.4, 117.5, 115.1, 113.6, 101.0, 68.5, 55.2, 32.2, 28.3, 25.2, 25.1. HRMS (ESI) calculated for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 434.1574, found 434.1577.</ce:para>
                        <ce:para id="p0290" view="all">N-Hydroxy-8-((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)octanamide (<ce:bold>11c</ce:bold>) The titled compound <ce:bold>11c</ce:bold> was obtained from <ce:bold>10c</ce:bold> following the general procedure described for <ce:bold>11a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>11c</ce:bold> (67%) as a white solid. M.p. 132.5–134.4 °C; IR (KBr): 3198, 2932, 1632, 1514, 1446, 1252, 1028, 828 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.38 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 8.69 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 8.42 (s, 1H), 8.02 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.53 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.15 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.07 (dd, <ce:italic>J</ce:italic> = 8.9, 2.3 Hz, 1H), 7.00 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 4.11 (s, 2H), 3.79 (s, 3H), 1.95 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.81–1.71 (m, 2H), 1.55–1.47 (m, 2H), 1.41 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 1.29 (dd, <ce:italic>J</ce:italic> = 17.9, 9.9 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 174.6, 169.1, 163.1, 159.0, 153.5, 130.1, 126.9, 124.1, 123.3, 117.5, 115.1, 113.6, 101.0, 68.5, 55.2, 32.3, 28.5, 28.5, 28.4, 25.4, 25.1. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">27</ce:inf>NNaO<ce:inf loc="post">6</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 448.1731, found 448.1733.</ce:para>
                        <ce:para id="p0295" view="all">N-Hydroxy-6-((5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanamide (<ce:bold>11d</ce:bold>) The titled compound <ce:bold>11d</ce:bold> was obtained from <ce:bold>10d</ce:bold> following the general procedure described for <ce:bold>11a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>11d</ce:bold> (66%) as a white solid. M.p. 167.0–168.3 °C; IR (KBr): 3063, 2951, 1665, 1609, 1288, 1178, 1048, 835 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.92 (s, 1H), 10.40 (s, 1H), 8.71 (s, 1H), 8.45 (s, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.01 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 6.66 (s, 1H), 6.40 (s, 1H), 4.08 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.79 (s, 3H), 1.98 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.73 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.56 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.40 (q, <ce:italic>J</ce:italic> = 7.8 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 180.3, 169.0, 164.7, 161.7, 159.2, 157.5, 154.7, 130.2, 122.8, 122.2, 113.7, 105.3, 98.4, 92.9, 68.4, 55.2, 32.2, 28.2, 25.1, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">23</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 436.1367, found 436.1365.</ce:para>
                        <ce:para id="p0300" view="all">N-Hydroxy-7-((5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)heptanamide (<ce:bold>11e</ce:bold>) The titled compound <ce:bold>11e</ce:bold> was obtained from <ce:bold>10e</ce:bold> following the general procedure described for <ce:bold>11a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>11e</ce:bold> (65%) as a white solid. M.p. 172.3–173.4 °C; IR (KBr): 3175, 2829, 1666, 1572, 1516, 1175, 1048, 834 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.92 (s, 1H), 10.39 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 8.69 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 8.45 (s, 1H), 7.56–7.46 (m, 2H), 7.05–6.97 (m, 2H), 6.66 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.40 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.07 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.79 (s, 3H), 1.95 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.71 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.55–1.46 (m, 2H), 1.40 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.30 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 180.7, 169.5, 165.1, 162.2, 159.6, 158.0, 155.2, 130.6, 123.2, 122.6, 114.2, 105.8, 98.8, 93.3, 68.9, 55.6, 32.7, 28.7, 25.6, 25.5. HRMS (ESI) calculated for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 450.1523, found 450.1521.</ce:para>
                        <ce:para id="p0305" view="all">N-Hydroxy-8-((5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)octanamide (<ce:bold>11f</ce:bold>) The titled compound <ce:bold>11f</ce:bold> was obtained from <ce:bold>10f</ce:bold> following the general procedure described for <ce:bold>11a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>11f</ce:bold> (62%) as a white solid. M.p. 162.3–163.1 °C; IR (KBr): 3285, 2931, 1665, 1609, 1572, 1516, 1176, 1048, 835 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.92 (s, 1H), 10.41 (s, 1H), 8.70 (s, 1H), 8.45 (s, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.01 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.64 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.39 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.07 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.79 (s, 3H), 1.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.71 (q, <ce:italic>J</ce:italic> = 6.9 Hz, 2H), 1.50 (p, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.41–1.23 (m, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 180.3, 169.1, 164.7, 161.7, 157.5, 154.7, 130.3, 122.8, 122.1, 113.7, 98.4, 92.9, 68.5, 55.2, 32.3, 28.5, 28.5, 28.4, 25.3, 25.1. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">27</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 464.168, found 464.1681.</ce:para>
                        <ce:para id="p0310" view="all">Methyl-6-((2-(4-(2-(dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>14a</ce:bold>) To a solution of <ce:bold>7j</ce:bold> (2.00 g, 5.02 mmol) in dioxane (50 mL) was added K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (4.15 g, 30.0 mmol), 2-Dimethylaminoethyl chloride hydrochloride (3.60 g, 25.0 mmol) and water (9 mL) under Ar. The mixture was reflux for overnight. The mixture was then diluted with EtOAc (50 mL) and washed with saturated NaCl solution (150 mL), dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>14a</ce:bold> (1.45 g, 62%) as a pale yellow solid. mp 78.2–79.3 °C; IR (KBr): 3321, 2877, 1735, 1 643, 1610, 1182, 839 cm <ce:sup loc="post">−1</ce:sup>.<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.77 (s, 1H), 7.80 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.01 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.53 (s, 1H), 6.43 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 6.30 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.16 (t, <ce:italic>J</ce:italic> = 5.5 Hz, 2H), 4.00 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.66 (s, 3H), 2.82 (t, <ce:italic>J</ce:italic> = 5.4 Hz, 2H), 2.40 (s, 6H), 2.35 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.81 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.69 (q, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 1.50 (q, <ce:italic>J</ce:italic> = 8.0 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 164.6, 163.3, 161.1, 160.6, 157.2, 128.4, 123.5, 115.3, 104.6, 103.9, 98.4, 93.1, 68.4, 62.7, 54.9, 42.7, 33.2, 32.1, 28.1, 25.0, 24.8, 24.1. HRMS (ESI) calculated for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">31</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 492.1993, found 492.1992.</ce:para>
                        <ce:para id="p0315" view="all">Ethyl-7-((2-(4-(2-(dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)heptanoate (<ce:bold>14b</ce:bold>) The titled compound <ce:bold>14b</ce:bold> was obtained from <ce:bold>7k</ce:bold> and 2-Dimethylaminoethyl chloride hydrochloride following the general procedure described for <ce:bold>14a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>14b</ce:bold> (59%) as a pale yellow solid. M.p. 73.2–74.7 °C; IR (KBr): 3105, 2931, 1729, 1648, 1609, 1244, 1129, 835. cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.76 (s, 1H), 7.81 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.02 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.55 (s, 1H), 6.45 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.28 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 4.12 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 4.01 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.99 (t, <ce:italic>J</ce:italic> = 5.2 Hz, 2H), 2.54 (s, 6H), 2.31 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.88–1.73 (m, 2H), 1.71–1.61 (m, 2H), 1.49 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 1.40 (q, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 1.25 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.5, 165.1, 163.8, 161.3, 157.8, 128.2, 124.1, 115.1, 104.5, 98.6, 93.1, 68.6, 65.4, 60.4, 57.8, 45.4, 34.4, 28.9, 28.9, 25.8, 24.9, 14.4. HRMS (ESI) calculated for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">31</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 520.2306, found 520.2309.</ce:para>
                        <ce:para id="p0320" view="all">Methyl-8-((2-(4-(2-(dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)octanoate (<ce:bold>14c</ce:bold>) The titled compound <ce:bold>14c</ce:bold> was obtained from <ce:bold>7l</ce:bold> and 2-Dimethylaminoethyl chloride hydrochloride following the general procedure described for <ce:bold>14a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>14c</ce:bold> (65%) as a pale yellow solid. M.p. 79.5–81.3 °C; IR (KBr): 3074, 2941, 1734, 1656, 1607, 1162, 841 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.78 (s, 1H), 7.81 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.01 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.54 (s, 1H), 6.44 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.17 (t, <ce:italic>J</ce:italic> = 5.4 Hz, 2H), 4.00 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.66 (s, 3H), 2.83 (t, <ce:italic>J</ce:italic> = 5.4 Hz, 2H), 2.41 (s, 6H), 2.31 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.79 (p, <ce:italic>J</ce:italic> = 6.8, 6.0 Hz, 2H), 1.63 (p, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.46 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 1.36 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 174.3, 165.0, 163.8, 162.0, 161.6, 157.7, 128.0, 123.7, 115.0, 105.4, 104.3, 98.5, 93.0, 68.6, 65.9, 57.9, 51.53, 45.7, 34.0, 29.0, 29.0, 28.9, 25.8, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">35</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 520.2306, found 520.2305.</ce:para>
                        <ce:para id="p0325" view="all">Methyl-6-(4-(7-(3-(dimethylamino)propoxy)-5-hydroxy-4-oxo-4H-chromen-2-yl)phenoxy)hexanoate (<ce:bold>14d</ce:bold>) The titled compound <ce:bold>14d</ce:bold> was obtained from <ce:bold>7j</ce:bold> and 3-Dimethylaminopropylchloride hydrochloride following the general procedure described for <ce:bold>14a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>14d</ce:bold> (63%) as a pale yellow solid. M.p. 81.1–82.8 °C; IR (KBr): 2944, 2859, 1737, 1654, 1605, 1503, 1351, 1268, 1165, 1116, 1031, 833, 764 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.76 (s, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.96 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.51 (s, 1H), 6.42 (s, 1H), 6.29 (s, 1H), 4.10 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 4.00 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.66 (s, 3H), 2.73 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 2.46 (s, 6H), 2.34 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 2.13 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.81 (p, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.70 (p, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.50 (q, <ce:italic>J</ce:italic> = 8.2 Hz, 2H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 174.1, 164.9, 163.9, 162.1, 161.8, 157.7, 128.1, 123.7, 115.0, 105.5, 104.3, 98.5, 93.0, 68.4, 66.0, 56.1, 51.7, 44.8, 34.0, 28.7, 26.5, 25.6, 24.7; HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">33</ce:inf>NO<ce:inf loc="post">7</ce:inf>Na<ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 506.2149, found 506.2150.</ce:para>
                        <ce:para id="p0330" view="all">Ethyl-7-(4-(7-(3-(dimethylamino)propoxy)-5-hydroxy-4-oxo-4H-chromen-2-yl)phenoxy)heptanoate (<ce:bold>14e</ce:bold>) The titled compound <ce:bold>14e</ce:bold> was obtained from <ce:bold>7k</ce:bold> and 3-Dimethylaminopropylchloride hydrochloride following the general procedure described for <ce:bold>14a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>14e</ce:bold> (67%) as a pale yellow solid. M.p. 75.2–76.9 °C; IR (KBr): 2926, 2854, 1731, 1657, 1606, 1502, 1352, 1273, 1169, 1098, 1034, 833, 766 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.76 (s, 1H), 7.80 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.97 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.53 (s, 1H), 6.44 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 6.31 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.12 (q, <ce:italic>J</ce:italic> = 7.7, 7.1 Hz, 4H), 4.00 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.85 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 2.56 (s, 6H), 2.31 (q, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 2.21 (p, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 1.80 (p, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.66 (p, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.47 (q, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.39 (p, <ce:italic>J</ce:italic> = 7.4, 7.0 Hz, 2H), 1.24 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 3H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.3, 173.7, 165.0, 163.8, 162.0, 161.6, 157.6, 128.0, 123.7, 114.9, 105.4, 104.3, 98.5, 93.0, 68.5, 65.8, 60.3, 55.9, 44.3, 34.3, 28.8, 26.0, 25.7, 25.6, 24.8, 14.3; HRMS (ESI) calculated for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">37</ce:inf>NO<ce:inf loc="post">7</ce:inf>Na<ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 534.2462, found 534.2461.</ce:para>
                        <ce:para id="p0335" view="all">Methyl-8-(4-(7-(3-(dimethylamino)propoxy)-5-hydroxy-4-oxo-4H-chromen-2-yl)phenoxy)octanoate (<ce:bold>14f</ce:bold>) The titled compound <ce:bold>14f</ce:bold> was obtained from <ce:bold>7l</ce:bold> and 3-Dimethylaminopropylchloride hydrochloride following the general procedure described for <ce:bold>14a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>14f</ce:bold> (67%) as a pale yellow solid. M.p. 77.4–78.8 °C; IR (KBr): 2943, 2856, 1738, 1660, 1610, 1503, 1354, 1262, 1167, 1110, 1034, 828, 764 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.72 (s, 1H), 7.75 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.93 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.48 (s, 1H), 6.40 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.27 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.10 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.97 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.63 (s, 3H), 2.91 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 2.59 (s, 6H), 2.28 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 2.25–2.17 (m, 2H), 1.76 (p, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 1.61 (p, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.43 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.39–1.28 (m, 4H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 174.2, 165.0, 163.8, 162.1, 161.5, 157.7, 128.0, 123.8, 114.9, 105.4, 104.3, 98.5, 93.0, 68.6, 65.7, 55.9, 51.5, 44.2, 34.1, 29.1, 29.0, 28.9, 25.8, 25.8, 24.9; HRMS (ESI) calculated for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">37</ce:inf>NO<ce:inf loc="post">7</ce:inf>Na<ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 534.2462, found 534.2463.</ce:para>
                        <ce:para id="p0340" view="all">6-((2-(4-(2-(Dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyhexanamide (<ce:bold>15a</ce:bold>) To a solution of Hydroxylamine hydrochloride (614 mg, 8.84 mmol) in CH<ce:inf loc="post">3</ce:inf>OH (5 mL) was added KOH (738 mg, 13.2 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 h and white solid was formed. Then the residue was filtered and afforded hydroxylamine in CH<ce:inf loc="post">3</ce:inf>OH solution. Compound <ce:bold>14a</ce:bold> (100 mg, 0.213 mmol) was dissolved in CH<ce:inf loc="post">3</ce:inf>OH (obtained above, 2 mL) at 0 °C and stirred at RT for 0.5 h. Yellow solids was formed. The residue was filtered and washed with CH<ce:inf loc="post">3</ce:inf>OH. The resulting yellow solid compound was dissolved in 1 M HCl/CH<ce:inf loc="post">3</ce:inf>OH (1 mL) and stirred for 0.5 h at 0 °C. Then the volatiles was evaporated under reduced pressure to afford compound <ce:bold>15a</ce:bold> (105 mg, 89%) as a yellow solid. M.p. 180.8–182.4 °C; IR (KBr): 3045, 2937, 1744, 1677, 1608, 1179, 842. cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.89 (s, 1H), 10.95 (s, 1H), 10.45 (s, 1H), 8.21–8.03 (m, 2H), 7.29–7.14 (m, 2H), 6.98 (d, <ce:italic>J</ce:italic> = 2.4 Hz, 1H), 6.80 (s, 1H), 6.37 (s, 1H), 4.50 (d, <ce:italic>J</ce:italic> = 5.3 Hz, 2H), 4.08 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 2H), 3.58–3.42 (m, 2H), 2.85 (t, <ce:italic>J</ce:italic> = 3.4 Hz, 6H), 1.99 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.73 (q, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.57 (p, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.39 (p, <ce:italic>J</ce:italic> = 7.6 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 164.6, 163.6, 161.7, 157.3, 128.4, 122.7, 115.1, 104.7, 103.7, 98.4, 93.1, 66.2, 57.6, 45.6, 32.3, 28.2, 24.9. HRMS (ESI) calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+H]<ce:sup loc="post">+</ce:sup> 471.2126, found 471.2125.</ce:para>
                        <ce:para id="p0345" view="all">7-((2-(4-(2-(Dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyheptanamide(<ce:bold>15b</ce:bold>) The titled compound <ce:bold>15b</ce:bold> was obtained from <ce:bold>14b</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold> as a yellow solid (91%). M.p. 170.4–171.6 °C; IR (KBr): 2937, 2855, 1658, 1603, 1502, 1202, 837 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.91 (s, 1H), 10.35 (s, 1H), 8.68 (s, 1H), 8.06 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 7.13 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 6.94 (s, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.37 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.17 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 4.09 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 2.65 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 2.23 (s, 6H), 1.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.73 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.52 (p, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.41 (p, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.31 (q, <ce:italic>J</ce:italic> = 7.6 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.0, 164.6, 163.6, 161.2, 157.3, 128.4, 115.1, 103.7, 66.2, 57.6, 45.6, 32.2, 28.3, 25.2, 25.1. HRMS (ESI) calculated for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+H]<ce:sup loc="post">+</ce:sup> 485.2053, found 485.2054.</ce:para>
                        <ce:para id="p0350" view="all">8-((2-(4-(2-(Dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyoctanamide(<ce:bold>15c</ce:bold>) The titled compound <ce:bold>15c</ce:bold> was obtained from <ce:bold>14c</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold>. Washed with CH<ce:inf loc="post">3</ce:inf>OH to afford compound <ce:bold>15c</ce:bold> (93%) as a yellow solid. mp 190.5–192.1 °C; IR (KBr): 3064, 2855, 1654, 1608, 1508, 1174, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.02 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.12 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.85 (s, 1H), 6.65 (s, 1H), 6.26 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.15 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 4.05 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 2.65 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 2.23 (s, 6H), 1.94 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.71 (q, <ce:italic>J</ce:italic> = 6.9 Hz, 2H), 1.57–1.44 (m, 2H), 1.44–1.27 (m, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.5, 168.9, 164.4, 162.9, 161.6, 157.6, 128.2, 122.8, 115.0, 103.9, 98.7, 92.0, 68.2, 66.2, 57.6, 45.6, 32.3, 28.6, 28.5, 28.4, 25.3, 25.2. HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+H]<ce:sup loc="post">+</ce:sup> 499.2439, found 499.2440.</ce:para>
                        <ce:para id="p0355" view="all">6-((2-(4-(3-(Dimethylamino)propoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyhexanamide hydrochloride (<ce:bold>15d</ce:bold>) The titled compound <ce:bold>15d</ce:bold> was obtained from <ce:bold>14d</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold> as a yellow solid (94%). M.p. 162.3–163.9 °C; IR (KBr): 2935, 2865, 2677, 1661, 1605, 1582, 1501, 1338, 1241, 1171, 1051, 830, 764 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic>13.01 (s, 1H), 10.99 (s, 1H), 10.45 (s, 1H), 8.07 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.13 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.94 (s, 1H), 6.79 (s, 1H), 6.35 (s, 1H), 4.19 (d, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 4.08 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 3.25–3.15 (m, 2H), 2.76 (s, 6H), 2.20 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 2.03–1.94 (m, 2H), 1.73 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.55 (p, <ce:italic>J</ce:italic> = 7.9, 7.5 Hz, 2H), 1.45–1.32 (m, 2H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 169.0, 164.6, 163.4, 161.4, 161.1, 157.2, 128.4, 122.9, 115.0, 104.7, 103.7, 98.4, 93.1, 68.4, 65.4, 53.8, 42.0, 32.2, 28.2, 25.1, 24.9, 23.7; HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+H]<ce:sup loc="post">+</ce:sup> 485.2282, found 485.2281.</ce:para>
                        <ce:para id="p0360" view="all">7-((2-(4-(3-(Dimethylamino)propoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyheptanamide hydrochloride (<ce:bold>15e</ce:bold>) The titled compound <ce:bold>15e</ce:bold> was obtained from <ce:bold>14e</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold> as a yellow solid (97%). M.p. 166.1–167.4 °C; IR (KBr): 2925, 2856, 2650, 1659, 1606, 1580, 1500, 1340, 1244, 1186, 1033, 838, 769 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.83 (s, 1H), 10.99 (s, 1H), 10.40 (s, 1H), 8.04 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.11 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.89 (s, 1H), 6.74 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.32 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.18 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 4.05 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 3.21 (dt, <ce:italic>J</ce:italic> = 10.8, 5.5 Hz, 2H), 2.77 (d, <ce:italic>J</ce:italic> = 4.9 Hz, 6H), 2.23–2.16 (m, 2H), 1.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.70 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.51 (p, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.44–1.36 (m, 2H), 1.33–1.27 (m, 2H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 169.1, 164.6, 163.4, 161.4, 161.1, 157.2, 128.3, 122.9, 115.1, 104.6, 103.7, 98.3, 93.0, 68.4, 65.3, 53.8, 42.0, 32.2, 28.3, 25.1, 25.0, 23.7; HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+H]<ce:sup loc="post">+</ce:sup> 499.2439, found 499.2437.</ce:para>
                        <ce:para id="p0365" view="all">8-((2-(4-(3-(Dimethylamino)propoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyoctanamide hydrochloride (<ce:bold>15f</ce:bold>) The titled compound <ce:bold>15f</ce:bold> was obtained from <ce:bold>14f</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold> as a yellow solid (93%). m.p. 171.4–172.8 °C; IR (KBr): 2944, 2857, 2679, 1662, 1608, 1583, 1502, 1354, 1261, 1169, 1034, 828, 763 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.86 (s, 1H), 10.43 (s, 1H), 8.03 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.10 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.89 (s, 1H), 6.75–6.73 (m, 1H), 6.31 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.16 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 4.04 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 2.67 (s, 6H), 2.15 (p, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 1.95 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.69 (q, <ce:italic>J</ce:italic> = 7.0 Hz, 2H), 1.49 (p, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.42–1.23 (m, 6H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 169.1, 164.6, 163.4, 161.4, 161.1, 157.2, 128.3, 122.8, 115.0, 104.6, 103.7, 98.3, 93.0, 68.4, 65.5, 54.0, 42.4, 32.2, 28.5, 28.4, 28.4, 25.3, 25.1, 24.1; HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">37</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+H]<ce:sup loc="post">+</ce:sup> 513.2595, found 513.2596.</ce:para>
                        <ce:para id="p0370" view="all">Methyl-6-((5-hydroxy-2-(4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanoate(<ce:bold>19a</ce:bold>) To a solution of <ce:bold>7j</ce:bold> (1.00 g, 2.51 mmol) in DMF (25 mL) was added K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (694 mg, 5.02 mmol) and compound 1,2-dibromoethane (935 mg, 4.97 mmol) under Ar. The mixture was stirred at 70 °C for 6 h. The mixture was then diluted with EtOAc (200 mL) and washed with saturated NaCl solution (50 mL), dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and concentrated under reduced pressure to afford a mixture of compound <ce:bold>18</ce:bold> as a yellow solid, which was used directly in the next step without further purification. To a solution of <ce:bold>18</ce:bold> in acetone (25 mL) was added K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (935 mg, 6.76 mmol) and compound 1-methylpiperazine (0.55 mL, 5.00 mmol) under Ar. The mixture was stirred at 70 °C for 6 h. The mixture was then diluted with EtOAc (100 mL) and washed with saturated NaCl solution (50 mL), dried over Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>19a</ce:bold> (0.277 g, 21% for two steps) as a pale yellow solid. M.p. 100.5–101.9 °C; IR (KBr): 2931, 2821, 1742, 1639, 1610, 1172, 834 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.79 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.89–7.78 (m, 2H), 7.02 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 6.57 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.47 (d, <ce:italic>J</ce:italic> = 2.8 Hz, 1H), 6.34 (s, 1H), 4.26–4.13 (m, 2H), 4.03 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 3.69 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 3H), 2.92–2.84 (m, 2H), 2.64 (d, <ce:italic>J</ce:italic> = 49.5 Hz, 6H), 2.36 (d, <ce:italic>J</ce:italic> = 5.3 Hz, 5H), 1.84 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.72 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 1.52 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 1.25 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 174.0, 164.9, 163.9, 162.1, 161.7, 157.7, 128.0, 123.7, 115.0, 105.5, 104.4, 98.5, 92.98, 68.3, 66.2, 56.9, 55.0, 51.6, 33.9, 28.7, 25.6, 24.6. HRMS (ESI) calculated for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">36</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 547.2415, found 547.2413.</ce:para>
                        <ce:para id="p0375" view="all">Methyl-6-((5-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>19b</ce:bold>) The titled compound <ce:bold>19b</ce:bold> was obtained from <ce:bold>7j</ce:bold> and morpholine following the general procedure described for <ce:bold>19a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>19b</ce:bold> (26% for two steps) as a pale yellow solid. mp 98.3–100.1 °C; IR (KBr):.2958, 2842, 1752, 1633, 1169, 841 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.82–12.76 (m, 1H), 7.87–7.76 (m, 2H), 7.08–6.95 (m, 2H), 6.59–6.54 (m, 1H), 6.46 (s, 1H), 6.34 (s, 1H), 4.19 (q, <ce:italic>J</ce:italic> = 4.9 Hz, 2H), 4.02 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 3.74 (t, <ce:italic>J</ce:italic> = 4.4 Hz, 4H), 3.71–3.64 (m, 3H), 2.85 (p, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 2.60 (d, <ce:italic>J</ce:italic> = 5.4 Hz, 4H), 2.35 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 1.85 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 1.72 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 1.57–1.45 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.6, 165.1, 164.0, 157.9, 128.2, 124.0, 115.2, 104.6, 98.6, 93.2, 68.4, 67.1, 66.3, 57.6, 54.3, 51.7, 34.1, 28.8, 25.7, 24.8. HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">33</ce:inf>NNaO<ce:inf loc="post">8</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 534.2098, found 534.2096.</ce:para>
                        <ce:para id="p0380" view="all">Methyl-6-((5-hydroxy-4-oxo-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>19c</ce:bold>) The titled compound <ce:bold>19c</ce:bold> was obtained from <ce:bold>7j</ce:bold> and piperidine following the general procedure described for <ce:bold>19a</ce:bold>. It was purified by chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>19c</ce:bold> (23% for two steps) as a pale yellow solid. M.p. 100.1–101.2 °C; IR (KBr): 2940, 2853, 1733, 1656, 1605, 1164, 832 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.77 (s, 1H), 7.80 (dd, <ce:italic>J</ce:italic> = 8.7, 2.8 Hz, 2H), 7.05–6.92 (m, 2H), 6.53 (d, <ce:italic>J</ce:italic> = 2.8 Hz, 1H), 6.44 (s, 1H), 6.31 (s, 1H), 4.25 (d, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 4.09–3.89 (m, 2H), 3.67 (d, <ce:italic>J</ce:italic> = 2.9 Hz, 3H), 2.90 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.64 (s, 4H), 2.41–2.29 (m, 2H), 1.82 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.70 (q, <ce:italic>J</ce:italic> = 7.9 Hz, 6H), 1.50 (dq, <ce:italic>J</ce:italic> = 13.9, 8.1 Hz, 4H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 173.9, 164.9, 162.1, 128.0, 123.8, 115.1, 105.5, 104.4, 98.5, 93.0, 68.3, 65.8, 57.5, 54.9, 51.5, 33.9, 28.7, 25.6, 25.3, 24.6, 23.7. HRMS (ESI) calculated for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">35</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 532.2306, found 532.2304.</ce:para>
                        <ce:para id="p0385" view="all">Methyl-6-((5-hydroxy-4-oxo-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>19d</ce:bold>) The titled compound <ce:bold>19d</ce:bold> was obtained from <ce:bold>7j</ce:bold> and tetrahydro-pyrrole following the general procedure described for <ce:bold>19a</ce:bold>. Column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 25:1) to afford compound <ce:bold>19d</ce:bold> (29% for two steps) as a pale yellow solid. M.p. 87.7–89.3 °C; IR (KBr): 2947, 2779, 1733, 1658, 1604, 1166, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.78 (s, 1H), 7.82 (dd, <ce:italic>J</ce:italic> = 8.9, 2.8 Hz, 2H), 7.03 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.56 (d, <ce:italic>J</ce:italic> = 2.8 Hz, 1H), 6.46 (s, 1H), 6.33 (d, <ce:italic>J</ce:italic> = 2.8 Hz, 1H), 4.30 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 4.02 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 2H), 3.68 (d, <ce:italic>J</ce:italic> = 2.8 Hz, 3H), 3.10 (s, 2H), 2.86 (s, 4H), 2.41–2.32 (m, 2H), 1.93 (s, 4H), 1.84 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.72 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 1.52 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 182.5, 165.0, 163.9, 162.2, 161.5, 157.8, 128.1, 124.0, 115.2, 104.5, 98.6, 93.1, 68.4, 54.8, 54.7, 51.7, 34.0, 28.8, 25.7, 24.7, 23.6. HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">33</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 518.2149, found 518.2148.</ce:para>
                        <ce:para id="p0390" view="all">N-hydroxy-6-((5-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanamide hydrochloride (<ce:bold>20a</ce:bold>) The titled compound <ce:bold>20a</ce:bold> was obtained from <ce:bold>19a</ce:bold> following the general procedure described for <ce:bold>14a</ce:bold> as a yellow solid (90%). M.p. 194.7–196.2 °C; IR (KBr): 2932, 2795, 1644, 1598, 1165, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.94 (s, 1H), 12.11 (s, 1H), 10.44 (s, 1H), 8.10 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.21 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.97 (s, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.36 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.56 (t, <ce:italic>J</ce:italic> = 4.6 Hz, 2H), 4.08 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.84 (s, 2H), 3.69 (d, <ce:italic>J</ce:italic> = 12.7 Hz, 4H), 3.56 (d, <ce:italic>J</ce:italic> = 15.4 Hz, 4H), 2.83 (s, 3H), 1.98 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.73 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.65–1.48 (m, 2H), 1.47–1.29 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 169.0, 164.6, 163.4, 161.1, 160.5, 157.3, 128.4, 123.5, 115.4, 104.7, 104.0, 98.4, 93.1, 68.4, 62.7, 32.2, 28.1, 25.0, 24.8. HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">36</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+H]<ce:sup loc="post">+</ce:sup> 526.2548, found 526.2549.</ce:para>
                        <ce:para id="p0395" view="all">N-hydroxy-6-((5-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-4-oxo-4H-chromen-7-yl)oxy)hexanamide hydrochloride (<ce:bold>20b</ce:bold>) The titled compound <ce:bold>20b</ce:bold> was obtained from <ce:bold>19b</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold> as a yellow solid (89%). M.p. 164.1–165.2 °C. IR (KBr): 3080, 2934, 1643, 1599, 1544, 1247, 1166, 832 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.88 (s, 1H), 10.95 (s, 1H), 10.44 (s, 1H), 8.10 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.19 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 6.97 (s, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.36 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.57 (t, <ce:italic>J</ce:italic> = 5.1 Hz, 2H), 4.08 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.53–3.47 (m, 4H), 3.02 (ddt, <ce:italic>J</ce:italic> = 17.1, 12.0, 6.0 Hz, 2H), 1.99 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.86–1.70 (m, 6H), 1.65–1.51 (m, 2H), 1.43–1.35 (m, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 168.9, 164.6, 163.4, 161.1, 160.6, 128.4, 115.3, 104.7, 103.9, 98.4, 93.1, 68.4, 62.7, 54.4, 52.6, 32.2, 28.1, 25. 0, 24.8, 22.3, 21.2. HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">33</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">8</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+H]<ce:sup loc="post">+</ce:sup> 513.2231, found 513.2232.</ce:para>
                        <ce:para id="p0400" view="all">N-Hydroxy-6-((5-hydroxy-4-oxo-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-4H-chromen-7-yl)oxy)hexanamide hydrochloride (<ce:bold>20c</ce:bold>) The titled compound <ce:bold>20c</ce:bold> was obtained from <ce:bold>19c</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold> as a yellow solid (94%). M.p. 185.7–186.8 °C; IR (KBr): 3219, 2928, 1643, 1599, 1398, 1247, 1165, 1116, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.86 (s, 1H), 10.37 (s, 1H), 8.08 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.18 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 6.95 (s, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.34 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.58 (t, <ce:italic>J</ce:italic> = 4.9 Hz, 2H), 4.06 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.98–3.86 (m, 4H), 3.57 (d, <ce:italic>J</ce:italic> = 3.3 Hz, 4H), 3.50 (d, <ce:italic>J</ce:italic> = 12.3 Hz, 2H), 3.21 (d, <ce:italic>J</ce:italic> = 11.6 Hz, 2H), 1.98 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.77–1.68 (m, 2H), 1.62–1.51 (m, 2H), 1.43–1.33 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 164.6, 163.4, 161.1, 160.6, 157.3, 128.4, 123.5, 115.3, 103.9, 98.4, 93.1, 68.4, 63.1, 54.6, 51.6, 32.2, 28.1, 25.0, 24.8, 24.1. HRMS (ESI) calculated for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+H]<ce:sup loc="post">+</ce:sup> 511.2439, found 511.2438.</ce:para>
                        <ce:para id="p0405" view="all">N-Hydroxy-6-((5-hydroxy-4-oxo-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-4H-chromen-7-yl)oxy)hexanamide hydrochloride (<ce:bold>20d</ce:bold>) The titled compound <ce:bold>20d</ce:bold> was obtained from <ce:bold>19d</ce:bold> following the general procedure described for <ce:bold>15a</ce:bold> as a yellow solid (92%). M.p. 176.6–177.9 °C; IR (KBr): 3199, 2947, 1643, 1599, 1248, 1165, 837 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.89 (s, 1H), 11.17 (s, 1H), 10.43 (s, 1H), 8.19–8.04 (m, 2H), 7.25–7.16 (m, 2H), 6.98 (s, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.37 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 4.50 (t, <ce:italic>J</ce:italic> = 5.1 Hz, 2H), 4.09 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.60 (dt, <ce:italic>J</ce:italic> = 11.1, 5.7 Hz, 4H), 3.11 (dq, <ce:italic>J</ce:italic> = 15.1, 8.1 Hz, 2H), 2.00 (dt, <ce:italic>J</ce:italic> = 14.6, 5.6 Hz, 4H), 1.91 (dd, <ce:italic>J</ce:italic> = 7.8, 5.0 Hz, 2H), 1.74 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.61–1.52 (m, 2H), 1.44–1.36 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 181.9, 168.9, 163.4, 161.1, 160.7, 157.3, 128.4, 115.3, 104.7, 103.9, 98.4, 93.1, 68.4, 63.6, 53.6, 52.4, 32.2, 28.1, 25.0, 24.8, 22.6. HRMS (ESI) calculated for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">33</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+H]<ce:sup loc="post">+</ce:sup> 497.2282, found 497. 2280.</ce:para>
                        <ce:para id="p0410" view="all">1-(2,4,6-Trihydroxyphenyl)ethan-1-one (<ce:bold>22</ce:bold>) Aluminum trichloride (42.30 g, 317.2 mmol) was slowly added to a solution of phloroglucinol <ce:bold>21</ce:bold> (10.00 g, 79.30 mmol) in 1,2-dichloroethane/nitrobenzene (1:1, 150.0 mL) at 0 °C. After stirring at this temperature for 10 min under a nitrogen atmosphere, acetyl chloride (9.300 g, 119.0 mmol) was added dropwise. The ice bath was removed and the mixture was reflux for 5 h. The crude reaction mixture was cooled to rt and then quenched with water (100.0 mL). The mixture was extracted with EtOAc (300.0 mL), washed with saturated solution of NaCl, and concentrated in vacuum. Recrystallization by EtOAc to afford compound <ce:bold>22</ce:bold> (11.00 g, 82.5%). mp 212.1–214.1 °C; IR (KBr): 3287, 1630, 1522, 1171, 818 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.22 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 10.35 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 5.80 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 2.54 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 202.5, 164.8, 164.3, 104.0, 94.5, 32.4. HRMS (ESI) calculated for C<ce:inf loc="post">8</ce:inf>H<ce:inf loc="post">8</ce:inf>NaO<ce:inf loc="post">4</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 191.0315, found 191.0317.</ce:para>
                        <ce:para id="p0415" view="all">1-(2-Hydroxy-4,6-dimethoxyphenyl)ethan-1-one (<ce:bold>23</ce:bold>) Potassium carbonate (16.50 g, 119.0 mmol) was added to a solution of compound <ce:bold>22</ce:bold> (10.00 g, 59.50 mmol) in ethanol (114.0 mL), and the reaction mixture was added dropwise with methyl p-toluenesulfonate (30.00 g, 161.0 mmol), and then reflux for 12 h. The reaction was diluted with water and extracted with EtOAc (300.0 mL). The solvent was removed. Recrystallization from ethanol (20.00 mL) gave compound <ce:bold>23</ce:bold> (7.230 g, 62.0%) as a white crystal. mp 70.7–72.6 °C; IR (KBr): 3100, 1619, 1205, 1081, 836 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 14.02 (s, 1H), 6.05 (d, <ce:italic>J</ce:italic> = 2.4 Hz, 1H), 5.92 (d, <ce:italic>J</ce:italic> = 2.4 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 2.61 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 203.1, 167.6, 166.1, 162.9, 106.0, 93.5, 90.7, 55.5, 32.9. HRMS (ESI) calculated for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">12</ce:inf>NaO<ce:inf loc="post">4</ce:inf>
                           <ce:sup loc="post">+</ce:sup> [M+Na]<ce:sup loc="post">+</ce:sup> 219.0628, found 219.0625.</ce:para>
                        <ce:para id="p0420" view="all">4-(Benzyloxy)benzaldehyde (<ce:bold>24</ce:bold>) Anhydrous potassium carbonate (22.60 g, 164.0 mmol) was added to a solution of p-hydroxybenzaldehyde (10.00 g, 81.90 mmol) in DMF (80.00 mL), and benzyl bromide (15.40 g, 90.10 mmol) was added. The reaction was stirred at 60 °C for 2 h. It was then cooled to room temperature. The mixture was extracted with EtOAc (300.0 mL). Recrystallization from PE/EA gave compound <ce:bold>24</ce:bold> (14.9 g, 87.6%) as a white crystal. mp 67.7–69.6 °C; IR (KBr): 2929, 2745, 1687, 1600, 1745, 1260, 1164, 1018, 866, 735 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.88 (s, 1H), 7.89–7.79 (m, 2H), 7.49–7.32 (m, 5H), 7.12–7.03 (m, 2H), 5.14 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 190.8, 163.8, 136.0, 132.0, 130.2, 128.8, 128.4, 127.5, 115.2, 70.3. HRMS (ESI) calculated for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">12</ce:inf>NaO<ce:inf loc="post">2</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 235.0730, found 235.0731.</ce:para>
                        <ce:para id="p0425" view="all">(E)-3-(4-(Benzyloxy)phenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one (<ce:bold>25</ce:bold>) A solution of compound <ce:bold>23</ce:bold> (10.00 g, 50.90 mmol), compound <ce:bold>24</ce:bold> (12.98 g, 61.08 mmol) and KOH (20.00 g, 356.3 mmol) in methanol (300.0 mL) were stirred and reflux for 20 h. The reaction mixture was neutralized with 1 N HCl to pH∼7 and extracted with DCM (600.0 mL). Solvent was removed. Recrystallization from EtOAc gave compound <ce:bold>25</ce:bold> (6.760 g, 61.7%). mp 151.7–153.6 °C; IR (KBr): 3013, 1630, 1553, 1346, 1153, 1115, 825 cm <ce:sup loc="post">−1</ce:sup>.<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 14.41 (s, 1H), 7.79 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 7.59–7.49 (m, 2H), 7.47–7.30 (m, 5H), 7.03–6.94 (m, 2H), 6.10 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 5.96 (d, <ce:italic>J</ce:italic> = 2.4 Hz, 1H), 5.11 (s, 2H), 3.91 (s, 3H), 3.83 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 187.8, 163.6, 161.3, 137.6, 131.8, 125.4, 123.9, 123.8, 123.4, 122.7, 120.5, 110.5, 89.1, 86.5, 65.4, 51.1, 50.8. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">22</ce:inf>NaO<ce:inf loc="post">5</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 413.1359, found 413.1358.</ce:para>
                        <ce:para id="p0430" view="all">2- (4-(Benzyloxy)phenyl)-5,7-dimethoxy-4H-chromen-4-one (<ce:bold>26</ce:bold>) The compound of <ce:bold>25</ce:bold> (6.500 g, 16.60 mmol), iodine (855.0 mg, 3.370 mmol) in DMSO (150.0 mL) were heated at 100 °C for 8 h. Then saturated sodium thiosulfate (200.0 mL) was added to remove the iodine. The reaction mixture was extracted with DCM, washed with water and evaporated. The crude extract was recrystallized from ethanol (160.0 mL) to give compound <ce:bold>26</ce:bold> (4.360 g, 67.0%) as a white crystal. mp 164–166 °C; IR (KBr): 2924, 2851, 1639, 1590, 1346, 1108, 835 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.88–7.77 (m, 2H), 7.52–7.31 (m, 5H), 7.13–7.03 (m, 2H), 6.60 (s, 1H), 6.55 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 6.37 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 5.14 (s, 2H), 3.96 (s, 3H), 3.91 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 177.7, 163.9, 161.2, 160.9, 160.6, 136.3, 128.7, 128.3, 127.6, 127.5, 124.1, 115.2, 107.8, 96.1, 92.8, 70.2, 56.5, 55.8. HRMS (ESI) calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">20</ce:inf>NaO<ce:inf loc="post">5</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 411.1203, found 411.1205.</ce:para>
                        <ce:para id="p0435" view="all">3- (4-Hydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one (<ce:bold>27</ce:bold>) To a solution of compound <ce:bold>26</ce:bold> (5.000 g, 12.87 mmol) in THF(300.0 mL) was added 10% Pd/C (2.500 g). The mixture was stirred at room temperature for 18 h. Then the mixture was filtered and washed by THF and MeOH, concentrated under reduced pressure to afford compound <ce:bold>27</ce:bold> (3.200, 85.0%) as a pale yellow solid. mp 163–165 °C; IR (KBr): 3221, 2925, 1605, 1589, 1501, 1160 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.23 (s, 1H), 7.93–7.83 (m, 2H), 6.90 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 6.82 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 6.58 (s, 1H), 6.48 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 3.89 (s, 3H), 3.82 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 175.7, 163.6, 160.5, 160.2, 160.1, 159.1, 127.8, 121.4, 115.8, 106.1, 96.2, 93.3, 56.1, 55.9. HRMS (ESI) calculated for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">14</ce:inf>NaO<ce:inf loc="post">5</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 321.0733, found 321.0735.</ce:para>
                        <ce:para id="p0440" view="all">(4-(2-(Dimethylamino)ethoxy)phenyl)-5,7-dimethoxy-4H-chromen-4-one (<ce:bold>29</ce:bold>) Potassium carbonate (20.90 g, 151.0 mmol) was added to a solution of compound <ce:bold>27</ce:bold> (3.000 g, 10.10 mmol) in 1,4-dioxane (50.00 mL). N, N-Dimethyl-aminoethyl chloride hydrochloride <ce:bold>28</ce:bold> (14.50 g, 101.0 mmol) was added with stirring. The mixture was reacted under reflux conditions for 15 h. The resulting mixture was extracted with EtOAc, the combined organic phases were dried and concentrated. Recrystallization from ethanol (14.00 mL) gave compound <ce:bold>29</ce:bold> (1.900 g, 52.0%) as a pale yellow solid. mp 110–111 °C; IR (KBr): 3077, 2923, 1662, 1602, 1503, 1457, 1265 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.03–7.94 (m, 2H), 7.15–7.07 (m, 2H), 6.85 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 6.66 (s, 1H), 6.50 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.21 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 3.90 (s, 3H), 3.83 (s, 3H), 2.83 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 2.35 (s, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 176.2, 164.1, 161.2, 160.7, 160.1, 159.6, 128.2, 123.7, 115.5, 108.7, 107.3, 96.7, 93.8, 65.5, 57.2, 56.6, 56.4, 45.1. HRMS (ESI) calculated for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">23</ce:inf>NNaO<ce:inf loc="post">5</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 392.1468, found 392.1465.</ce:para>
                        <ce:para id="p0445" view="all">2-(4-(2-(Dimethylamino)ethoxy)phenyl)-5,7-dihydroxy-4H-chromen-4-one (<ce:bold>30</ce:bold>) The mixture of compound <ce:bold>29</ce:bold> (1.930 g, 5.430 mmol) and excess pyridine hydrochloride (45.00 g, 326.0 mmol) were heated at 120 °C for 8 h under Ar. Then the mixture was cooled to room temperature and washed by saturated NaHCO<ce:inf loc="post">3</ce:inf> to PH∼7. The mixture was extracted with EtOAc and the combined organic phases were dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 15:1) to afford compound <ce:bold>30</ce:bold> (1.160 g, 60%) as a pale yellow solid. mp 232.7–234.0 °C; IR (KBr): 3137, 2840, 1656, 1619, 1509, 1384, 1262, 1179, 824. cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.92 (s, 1H), 8.01 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 7.23–7.02 (m, 2H), 6.85 (s, 1H), 6.50 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.19 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.15 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 2.65 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 2.22 (s, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.2, 164.9, 162.0, 161.9, 128.8, 123.2, 115.5, 104.1, 103.9, 99.4, 94.5, 66.6, 58.0, 46.0. HRMS (ESI) calculated for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">19</ce:inf>NNaO<ce:inf loc="post">5</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 364.1155, found 364.1157.</ce:para>
                        <ce:para id="p0450" view="all">6-((2-(4-(2-(dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)hexanoate (<ce:bold>32</ce:bold>) The solution of compound <ce:bold>30</ce:bold> (1.02 g, 2.99 mmol), potassium carbonate (0.830 g, 5.98 mmol) in DMF (30 mL) was added methyl 6-bromohexanoate <ce:bold>31</ce:bold> (0.750 g, 3.59 mmol), and the mixture was reflux for 6 h. The reaction was diluted with water and extracted with EtOAc. The combined organic phases were dried and concentrated. The residue was purified by column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>: CH<ce:inf loc="post">3</ce:inf>OH = 40:1) to afford compound <ce:bold>32</ce:bold> (1.12 g, 80%) as a pale yellow solid. mp 84–85 °C; IR (KBr): 3233, 3577, 1654, 1621, 1519, 1346, 1241, 1189, 831 cm <ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.89 (s, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.14 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.92 (s, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.35 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 4.22 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 4.09 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.59 (s, 3H), 2.79 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 2.33 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 8H), 1.74 (p, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 1.60 (p, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 1.43 (qd, <ce:italic>J</ce:italic> = 9.4, 8.8, 6.1 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 182.4, 173.7, 165.0, 164.0, 162.0, 161.6, 157.7, 128.8, 123.3, 115.6, 104.2, 98.8, 93.6, 68. 8, 66.2, 57.6, 51.6, 45.6, 33.7, 28.5, 25.4, 24.6. HRMS (ESI) calculated for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">31</ce:inf>NNaO<ce:inf loc="post">7</ce:inf>
                           <ce:sup loc="post">+</ce:sup>[M+Na]<ce:sup loc="post">+</ce:sup> 492.1993, found 492.1995.</ce:para>
                        <ce:para id="p0455" view="all">6-((2-(4-(2-(Dimethylamino)ethoxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)-N-hydroxyhexanamide (<ce:bold>15a</ce:bold>) Compound <ce:bold>32</ce:bold> (1.00 g, 2.10 mmol) was dissolved in CH<ce:inf loc="post">3</ce:inf>OH (20 mL) at 0 °C. And the freshly prepared hydroxylamine methanol solution was added dropwise and stirred at room temperature for 0.5 h. A pile of yellow solid was formed. Solid was filtered and washed with water to afford compound <ce:bold>10</ce:bold> as yellow solid (1.02 g, 100%). Final compound <ce:bold>15a</ce:bold> was synthesized as described previously.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.3" view="all">
                        <ce:label>3.1.3</ce:label>
                        <ce:section-title id="sectitle0130">Cell lines and cell culture</ce:section-title>
                        <ce:para id="p0460" view="all">Human breast cancer cell lines MDA-MB-231 (ATCC CRM-HTB-26), MCF-7 (ATCC HTB-22™), T-47D (ATCC® HTB-133™), BCAP-37, Sum-159, human melanoma cell line A375 (ATCC CRL-1619), human pancreatic cancer cell line PANC-1 (ATCC CRL-1469), PC-3 (ATCC® CRL-1435™), human hepatocarcinoma cell line PLC (ATCC CRL-8024 ™), SMMC-7721, Bel-7402, human lung cancer cell line NCI–H460 (ATCC® HTB-177™), NCI–H1581 (ATCC® CRL-5878), and mouse breast cancer cell line 4T1 (ATCC CRL-2539), mouse melanoma cell line B16F10 (ATCC CRL-6475), were cultured in 1640 medium supplemented with 10% fetal bovine serum (FBS, Biological Industries (BI), 04-001-1A/B), 100 units/ml penicillin G, 0.1 mg/mL streptomycin (life science, P1400) at 37 °C in the presence of 5% CO<ce:inf loc="post">2</ce:inf>. Human lung adenocarcinoma cell line A549 (ATCC CRM-CCL-185), human hepatocarcinoma cell line Hep G2 (ATCC® HB-8065™), human breast cancer cell line MDA-MB-468 (ATCC® HTB-132™), BT-549 (ATCC® HTB-122™), were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS, Biological Industries (BI), 04-001-1A/B), 100 units/ml penicillin G, 0.1 mg/mL streptomycin (life science, P1400) at 37 °C in the presence of 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.4" view="all">
                        <ce:label>3.1.4</ce:label>
                        <ce:section-title id="sectitle0135">HDAC enzyme assay <ce:italic>in vitro</ce:italic>
                        </ce:section-title>
                        <ce:para id="p0465" view="all">The HDACs enzyme assay was based on a fluorescence release assay. Whole HeLa cells were lysed in buffer (20 mM HEPES, 25% V/V glycerin, 0.42 mM NaCl, 1.5 mM MgCl<ce:inf loc="post">2</ce:inf>, 0.2 mM EDTA (PH 8.0), 0.5 mM DTT) via sonicator, and the supernatant was collected by microthermal centrifugation at 15000<ce:italic>g</ce:italic> for 15 min. All the HDAC isoforms were purchased from SignalChem. Proteins were diluted by assay buffer containing 25 mM Tris (pH 8.0), 1 mM MgCl<ce:inf loc="post">2</ce:inf>, 0.1 mg/mL BSA, 137 mM NaCl, 2.7 mM KCl in a total volume of 90 μL. Compounds were diluted into 10 concentrations with assay buffer, and 10 μL of the dilution was added and pre-incubated with purified recombinant HDAC at room temperature for 10 min. Finally, the enzyme substrate (Boc-Lys(q-Ac)-AMC synthesized by our lab, 150 μM) was added, and the plate was incubated at 37 °C (for HeLa extract) or room temperature (for recombinant HDAC proteins) for 30 min in a final volume of 110 μL respectively. The reaction was stopped with 10 μL of stop buffer (10 mg/mL trypsin, 2 μM TSA diluted in assay buffer) for 45 min at 37 °C. Fluorescence was then analyzed with an excitation of 355 nm and an emission wavelength of 460 nm at Sprark 10 M plate reader. The IC<ce:inf loc="post">50</ce:inf> values were determined by analyzing normalized dose−response inhibition using Prism GraphPad 7 software.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.5" view="all">
                        <ce:label>3.1.5</ce:label>
                        <ce:section-title id="sectitle0140">Cell cytotoxicity assay</ce:section-title>
                        <ce:para id="p0470" view="all">MTT assays were used to assess the drug sensitivity of different cancer cell lines. Cells were seeded in 96-well plates at 8.0–15.0 × 10<ce:sup loc="post">3</ce:sup> cells per well for human cancer cell lines, and 5.0 × 10<ce:sup loc="post">3</ce:sup> cells per well for mouse cancer cell line 4T1 and B16F10 in a final volume of 100 μL. And then compounds were added at different concentrations after 24 h post-plating. After 48 h of drug incubation, 15 μL of MTT (5 mg/mL, MedChemExpress (MCE, HY-15924) solution was added to each well and incubation was continued for another 3–4 h. Supernatant was removed and formazan crystals were dissolved in 100 μL of dimethyl sulfoxide (DMSO). Optical density (OD) of formazan concentration was read at 490 and 570 nm with THERMO FISHER Multiskan FC. The concentrations required to inhibit growth by 50% (IC<ce:inf loc="post">50</ce:inf>) were calculated with GraphPad Prizm 7.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.6" view="all">
                        <ce:label>3.1.6</ce:label>
                        <ce:section-title id="sectitle0145">Colony formation assay</ce:section-title>
                        <ce:para id="p0475" view="all">For clonogenic assay, 0.4 × 10<ce:sup loc="post">3</ce:sup> MDA-MB-231 cells and 0.3 × 10<ce:sup loc="post">3</ce:sup> 4T1 cells respectively diluted in 2 mL culture medium were plated into 6-well culture plates. After incubation for 24 h, compound <ce:bold>15a</ce:bold>, SAHA and Apigenin were added with indicated concentrations, and the plates were incubated at 37 °C with 5% CO<ce:inf loc="post">2</ce:inf> for 7 days. During incubation, culture medium with compounds was replaced twice. Finally, cell colonies were stained using 0.05% crystal violet (Amresco) and clones containing more than 50 cells were counted.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.7" view="all">
                        <ce:label>3.1.7</ce:label>
                        <ce:section-title id="sectitle0150">Cell cycle assay</ce:section-title>
                        <ce:para id="p0480" view="all">MDA-MB-231(5 × 10<ce:sup loc="post">5</ce:sup> cells) and 4T1 (3 × 10<ce:sup loc="post">5</ce:sup> cells) cells were cultured in six-well plates for 24 h, followed by starvation for 24. Next, cells were treated without or with compounds for 24 h, harvested, and fixed with 70% ethanol at −20 °C. Fixed cells were treated with RNase A (1 mg/mL) at 37 °C for 30 min, and then stained with propidium iodide (50 Ag/mL) at room temperature for 15 min. Finally, cells were measured by BD flow cytometer and analyzed using Modified software.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.8" view="all">
                        <ce:label>3.1.8</ce:label>
                        <ce:section-title id="sectitle0155">Apoptosis assay</ce:section-title>
                        <ce:para id="p0485" view="all">MDA-MB-231 (3.5 × 105 cells) and (2 × 10<ce:sup loc="post">5</ce:sup> cells) were plated into six-well culture plates and treated without or with compounds (SAHA, Apigenin and <ce:bold>15a</ce:bold>) at indicated concentration for 72 h. The treated cells were then harvested by trypsinization and washed twice with cold PBS. Cell apoptosis was detected using an Annexin V-FITC/PI Apoptosis Detection kit (Beyotime, C1063) by BD flow cytometer.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.9" view="all">
                        <ce:label>3.1.9</ce:label>
                        <ce:section-title id="sectitle0160">Western blot analysis</ce:section-title>
                        <ce:para id="p0490" view="all">MDA-MB-231(5 × 10<ce:sup loc="post">5</ce:sup> per well) and 4T1 (3 × 10<ce:sup loc="post">5</ce:sup> per well) were seeded in 6-well culture plates, treated with compound at indicated concentrations for different time and lysed in RIPA lysis buffer supplemented with protease inhibitors cocktail/PMSF and dephosphorylase inhibitor NaF. The protein concentration was measured with the BCA Protein Assay kit (Beyotime Biotechnology, P0012). Equal amounts of proteins were electrophoresed by SDS-PAGE (8%–15%) under denaturing conditions and transferred onto the PDVF membranes (Millipore Corporation, IPVH00010). Membranes were blocked in 5% non-fat milk (BD Difco, 232100) and then incubated with primary antibodies. After being washed, the membranes were incubated with secondary antibodies, and detected by Luminescent Image Analyzer LSA 4000 (GE, Fairfield, CO, USA). Antibodies used in this study were: anti-Ac-H3 (sc-34262), anti-Ac-α-Tubulin (66200-1-Ig), anti-cleaved PARP (sc-8007), anti-cleaved Caspase-3(sc-7272), anti-β-Actin(#3700), anti-p53(10442-1-AP), anti-Bcl-2(12789-1-AP), anti-STAT3 (51076-2-AP), anti-p-STAT3 (#9145), anti-p21 (10355-1-AP) (Proteintech, North America, HQ, USA).</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.10" view="all">
                        <ce:label>3.1.10</ce:label>
                        <ce:section-title id="sectitle0165">PK study</ce:section-title>
                        <ce:para id="p0495" view="all">Sprague-Dawley male rats (220–350 g) were purchased from Academy of Military Medical Sciences (Beijing, China). For a single dose PK study of compound <ce:bold>15a</ce:bold>, 6 rats were divided into two groups: (A) PO of compound <ce:bold>15a</ce:bold> (20 mg/kg), (B) IV of compound <ce:bold>15a</ce:bold> (20 mg/kg). For IV study, 200 μL blood was collected from different rats at 2 min, 5 min, 10 min, 20 min, 30 min, 1 h, 4 h, 6 h and 8 h. For PO study, 200 μL blood was collected from different rats at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 12 h. Blood samples were treated with heparin to prevent coagulation. Blood samples were centrifuged for 10 min at 13000 rpm in a desktop centrifuge to collect plasma. 50 μL plasma samples were combined with 200 μL internal standard (buspirone 100 ng/mL) in acetonitrile/MeOH (1:1, v/v), and centrifuged at 15000 rpm for 10 min at 4 °C. The supernatant (100 μL) was collected and mixed with 5 part of 50% MeOH/water. Plasma drug concentration was determined by LC/MS-MS. Summary of LC/MS-MS method was provided in supporting information. The processed plasma concentration-time data were analyzed using non-compartmental analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.11" view="all">
                        <ce:label>3.1.11</ce:label>
                        <ce:section-title id="sectitle0170">Animal study</ce:section-title>
                        <ce:para id="p0500" view="all">The animal studies were approved by the Institutional Review Board of Nankai University. All animal studies were conducted according to protocols approved by the Animal Ethics Committee of Nankai University. A total volume of 0.1 mL PBS containing 5.0 × 10<ce:sup loc="post">5</ce:sup> 4T1 cells was injected subcutaneously into six-week-old Balb/c mice. Additionally, 3.5 × 10<ce:sup loc="post">6</ce:sup> MDA-MB-231 cells were injected subcutaneously into six-week-old Balb/C nude mice. All mice were kept in specific pathogen-free (SPF) environment. When the tumor volume reached about 50–100 mm<ce:sup loc="post">3</ce:sup>, the mice were randomly divided to vehicle control, compound SAHA and <ce:bold>15a</ce:bold> (n = 5 or 6 for each group) and control were treated with sterile water. Compound <ce:bold>15a</ce:bold> were suspended in sterile water containing 2% DMSO, and administered intraperitoneally at the dose of 20 mg/kg/day for Balb/c mice, while 25 mg/kg/day for Balb/C nude mice. Meanwhile, Compound <ce:bold>15a</ce:bold> were administered orally at the dose of 50 mg/kg/day for Balb/c mice. For SAHA, an oral dose of 150 mg/kg/day were selected. Tumor volume and mice weight were measured each day after the initiation of the treatment. Mice were executed and tumors were harvested on day 22 or 34 days respectively.</ce:para>
                     </ce:section>
                     <ce:section id="sec3.1.12" view="all">
                        <ce:label>3.1.12</ce:label>
                        <ce:section-title id="sectitle0175">Statistical analysis</ce:section-title>
                        <ce:para id="p0505" view="all">All statistical analyses were conducted using SPSS 19.0 software for Windows (Chicago, IL). Statistically significant differences were determined by Students’ <ce:italic>t</ce:italic>-test, and <ce:italic>P</ce:italic> values less than 0.05 were considered statistically significant in all cases.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:section-title id="sectitle0180">Notes</ce:section-title>
                  <ce:para id="p0510" view="all">The authors declare no competing financial interest.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0185">Declaration of competing interest</ce:section-title>
               <ce:para id="p0515" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0190">Acknowledgments</ce:section-title>
               <ce:para id="p0520" view="all">This work was supported by The <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100012166" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Key Research and Development Program of China</ce:grant-sponsor> (No. <ce:grant-number refid="gs3">2018YFA0507203</ce:grant-number>), the Fundamental Research Funds for the Central Universities, <ce:grant-sponsor id="gs4" sponsor-id="https://doi.org/10.13039/501100004945" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Nankai University</ce:grant-sponsor> (NO. <ce:grant-number refid="gs4">735-63201235</ce:grant-number>), the <ce:grant-sponsor id="gs5" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-sponsor id="gs6" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">NSFC</ce:grant-sponsor>, No. 81703343 and 81503019), National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China (No. 2019ZX09201001), Key <ce:grant-sponsor id="gs7" sponsor-id="https://doi.org/10.13039/100006190" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Research and Development</ce:grant-sponsor> Program of Tianjin City (No. <ce:grant-number refid="gs7">19YFZCSY00160</ce:grant-number>), <ce:grant-sponsor id="gs8" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Key Research Program Directing Project of Cangzhou City, China</ce:grant-sponsor> (No. <ce:grant-number refid="gs8">192106010</ce:grant-number>), <ce:grant-sponsor id="gs9" sponsor-id="https://doi.org/10.13039/501100006606" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Tianjin Natural Science Foundation, China</ce:grant-sponsor> (No. <ce:grant-number refid="gs9">17JCQNJC11700</ce:grant-number>), <ce:grant-sponsor id="gs10" sponsor-id="https://doi.org/10.13039/501100002858" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">China Postdoctoral Science Foundation</ce:grant-sponsor> (No. <ce:grant-number refid="gs10">2018M640824</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0195">Supplementary data</ce:section-title>
                  <ce:para id="p0525" view="all">The following is the Supplementary data to this article:</ce:para>
                  <ce:para id="p0530" view="all">The Supporting Information is available free of charge on the website.</ce:para>
                  <ce:para id="p0535" view="all">Procedure of synthesis of all tested compounds and the copies of <ce:sup loc="post">1</ce:sup>H/<ce:sup loc="post">13</ce:sup>C NMR Spectrum of all compounds and intermediates, HPLC trace of all tested compounds. (PDF).<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523420306498/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0200">Supplementary data</ce:section-title>
                  <ce:para id="p0540" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0010" xlink:href="https://doi.org/10.1016/j.ejmech.2020.112677" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.112677</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0205">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Peserico</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Simone</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Physical and functional HAT/HDAC interplay regulates protein acetylation balance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biomed. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2011</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>10</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">Peserico, A.; Simone, C. Physical and Functional HAT/HDAC Interplay Regulates Protein Acetylation Balance. J. Biomed. Biotechnol. 2011, 2011, 1−10.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Witt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Deubzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Milde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Oehme</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HDAC family: what are the cancer relevant targets?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8</sb:first-page>
                              <sb:last-page>21</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC Family: What Are the Cancer Relevant Targets? Cancer Lett. 2009, 277, 8−21.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>West</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Johnstone</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New and emerging HDAC inhibitors for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>124</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>30</sb:first-page>
                              <sb:last-page>39</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">West, A. C.; Johnstone, R. W. New and Emerging HDAC inhibitors for Cancer Treatment. J. Clin. Invest. 2014, 124, 30−39.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.B.</ce:given-name>
                                 <ce:surname>La Thangue</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hdac inhibitors in cancer biology: emerging mechanisms and clinical applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>90</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>94</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">Khan, O.; La Thangue, N. B. Hdac inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90, 85−94.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Falkenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Johnstone</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discovery</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>673</sb:first-page>
                              <sb:last-page>691</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">Falkenberg, K. J.; Johnstone, R. W. Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders. Drug Discovery 2014, 13, 673-691.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Conway</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Woster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Georg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epigenetics: novel therapeutics targeting epigenetics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>523</sb:first-page>
                              <sb:last-page>524</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">Conway, S. J.; Woster, P. M.; Shen, J. K.; Georg, G.; Wang, S. Epigenetics: Novel Therapeutics Targeting Epigenetics. J. Med. Chem. 2015, 58, 523−524.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Moskowitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Horwitz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting histone deacetylases in T-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Lymphoma</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1–14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">Moskowitz, A. J.; Horwitz, S. M. Targeting Histone Deacetylases in T-cell Lymphoma. Leukemia & Lymphoma 2016, 1-14.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>459</sb:first-page>
                              <sb:last-page>473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Zeng, H.; Qu, J.; Jin, N.; Xu, J.; Lin, C.; Chen, Y.; Yang, X.; He, X.; Tang, S.; Lan, X.; Yang, X.; Chen, Z.; Huang, M.; Ding, J.; Geng, M. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell 2016, 30, 459-473.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Vansteenkiste</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Van Cutsem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dumez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Ricker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Randolph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Schöffski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest. N. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>483</sb:first-page>
                              <sb:last-page>488</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">Vansteenkiste, J.; Van Cutsem, E.; Dumez, H.; Chen, C.; Ricker, J. L.; Randolph, S. S.; Schoffski, P. Early Phase II Trial of Oral Vorinostat in Relapsed or Refractory Breast, Colorectal, or Non-small Cell Lung Cancer. Invest. New Drugs 2008, 26, 483-488.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Blumenschein</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Kies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.A.</ce:given-name>
                                 <ce:surname>Papadimitrakopoulou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Ricker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Chiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Frankel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza<ce:italic>™</ce:italic>, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest. N. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>81</sb:first-page>
                              <sb:last-page>87</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Blumenschein Jr., G. R.; Kies, M. S.; Papadimitrakopoulou, V. A.; Lu, C.; Kumar, A. J.; Ricker, J. L.; Chiao, J. H.; Chen, C.; Frankel, S. R. Phase II Trial of the Histone Deacetylase Inhibitor Vorinostat (Zolinza™, Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Recurrent and/or Metastatic Head and Neck Cancer. Invest New Drugs 2008, 26, 81-87.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Luu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Morgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Leong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>McNamara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Portnow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Frankel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Doroshow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Gandara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aparicio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Somlo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase II trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in metastatic breast cancer: a California cancer consortium study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7138</sb:first-page>
                              <sb:last-page>7142</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">Luu, T. H.; Morgan, R. J.; Leong, L.; Lim, D.; McNamara, M.; Portnow, J.; Frankel, P.; Smith, D. D.; Doroshow, J. H.; Gandara, D. R.; Aparicio, A.; Somlo, G. A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Metastatic Breast Cancer: A California Cancer Consortium Study. Clin. Cancer Res. 2008, 14, 7138-7142.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Robey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Chakraborty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Basseville</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Luchenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bahr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Bates</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Histone deacetylase inhibitors: emerging mechanisms of resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2021</sb:first-page>
                              <sb:last-page>2031</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Robey, R. W.; Chakraborty, A. R.; Basseville, A.; Luchenko, V.; Bahr, J.; Zhan, Z.; Bates, S. E. Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance. Mol. Pharmaceutics 2011, 8, 2021-2031</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>O’Keefe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grandis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the IL-6/JAK/STAT3 signalling Axis in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>234</sb:first-page>
                              <sb:last-page>248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Johnson, D. E.; O’Keefe, R. A.; Grandis, J. R. Targeting the IL-6/JAK/STAT3 Signalling Axis in Cancer. Nat. Rev. Clin. Oncol. 2018, 15, 234-248.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in cancer inflammation and immunity: a leading role for STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">Yu, H.; Pardoll, D.; Jove, R. STATs in Cancer Inflammation and Immunity: a Leading Role for STAT3. Nat. Rev. Cancer. 2009, 9, 798-809.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>117</sb:first-page>
                              <sb:last-page>128</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Wang, Y,; Shen, Y.; Wang, S.; Shen, Q.; Zhou, X. Can. Lett. 2018, 28, 117-128.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.S.T.A.T.3</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A target to enhance antitumor immune response</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Top. Microbiol. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>344</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>59</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">Lee, H. STAT3: A Target to Enhance Antitumor Immune Response. Curr. Top. Microbiol. Immunol. 2011, 344, 41-59.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Burdelya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bhattacharya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gabrilovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Heller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coppola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Dalton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>54</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; Dalton, W.; Jove, R.; Pardoll, D.; Yu, H. Regulation of the Innate and Adaptive Immune Responses by Stat-3 Signaling in Tumor Cells. Nat. Med. 2004, 10, 48-54.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kujawski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3367</sb:first-page>
                              <sb:last-page>3377</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">Kujawski, M.; Kortylewski, M.; Lee, H.; Herrmann, A.; Kay, H.; Yu, H. Stat3 Mediates Myeloid Cell-dependent Tumor Angiogenesis in Mice. J. Clin. Invest. 2008, 118, 3367-3377.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Oh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Hwang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Sok</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Sung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.W.</ce:given-name>
                                 <ce:surname>Ham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.Y.</ce:given-name>
                                 <ce:surname>Hwang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-cancer effect of tectochrysin in NSCLC cells through overexpression of death receptor and inactivation of STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>353</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>95</sb:first-page>
                              <sb:last-page>103</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">Oh, S.; Hwang, C. J.; Song, S.; Jung, Y. Y.; Yun, H.; Sok, C. H.; Sung, H. C.; Yi, J.; Park, D. H.; Ham, Y. W.; Han, S. B.; Hwang, B. Y.; Hong, J. T. Anti-cancer Effect of Tectochrysin in NSCLC Cells through Overexpression of Death Receptor and Inactivation of STAT3. Can. Lett. 2014, 353, 95-103.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kumamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fujii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Myricetin directly targets JAK1 to inhibit cell transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>275</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17</sb:first-page>
                              <sb:last-page>26</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">Kumamoto, T.; Fujii, M.; Hou, D. Myricetin Directly Targets JAK1 to Inhibit Cell Transformation. Can. Lett. 2009, 275, 17-26.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Selvendiran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Koga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ueno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yoshida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Maeyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Torimura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kojiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sata</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4826</sb:first-page>
                              <sb:last-page>4834</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Selvendiran, K.; Koga, H.; Ueno, T.; Yoshida, T.; Maeyama, M.; Torimura, T.; Yano, H.; Kojiro, M.; Sata, M. Luteolin Promotes Degradation in Signal Transducer and Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the Antitumor Potential of Flavonoids. Cancer Res. 2006, 66, 4826-4834.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Singh-Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Banerjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Raffoul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Sarkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Hillman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Radiation-induced HIF-1α cell survival pathway is inhibited by soy isoflavones in prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>124</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1675</sb:first-page>
                              <sb:last-page>1684</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">Singh-Gupta, V.; Zhang, H.; Banerjee, S.; Kong, D.; Raffoul, J. J.; Sarkar, F. H.; Hillman, G. G. Radiation-Induced HIF-1α Cell Survival Pathway is Inhibited by Soy Isoflavones in Prostate Cancer Cells. Int. J. Cancer 2009, 124, 1675-1684.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc 37 and Hsp 90</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>104</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Zhao, M.; Ma, J.; Zhu, H.; Zhang, X.; Du, Z.; Xu, Y.; Yu, X. Apigenin Inhibits Proliferation and Induces Apoptosis in Human Multiple Myeloma Cells through Targeting the Trinity of CK2, Cdc37 and Hsp90. Mol. Cancer 2011, 10, 104-118.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sun1</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-κb signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>100216</sb:first-page>
                              <sb:last-page>100226</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">Ai, X.; Qin, Y.; Liu, H.; Cui, Z.; Li, M.; Yang, J.; Zhong, W.; Liu, Y.; Chen, S.; Sun1, T.; Zhou, H.; Yang, C. Apigenin Inhibits Colonic Inflammation and Tumorigenesis by Suppressing STAT3-NF-κB Signaling. Oncotarget 2017, 8, 100216-100226.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-S.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-S.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-S.</ce:given-name>
                                 <ce:surname>Gil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-H.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.E.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-T.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1927</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">Hong, J. Y.; Chung, K.-S.; Shin, J.-S.; Lee, J.-H.; Gil. H.-S.; Lee, H.-H.; Choi, E., Choi, J.-H.; Hassan, A. H. E.; Lee, Y. S.; Lee, K.-T. Cancers, 2019, 11, 1927.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Konduru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ahmad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Owais</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and antiproliferative activity of functionalized flavone-triazole-tetrahydropyran conjugates against human cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>552</sb:first-page>
                              <sb:last-page>564</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">Ahmed, N.; Konduru, N. K.; Ahmad, S.; Owais, M. Design, Synthesis and Antiproliferative Activity of Functionalized Flavone-Triazole-tetrahydropyran Conjugates against Human Cancer Cell Lines. Eur. J. Med. Chem. 2014, 82, 552-564.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gobbi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Rampa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Belluti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Piazzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Valenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Caputo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zampiron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carrara</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3662</sb:first-page>
                              <sb:last-page>3669</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Gobbi, S.; Rampa, A.; Bisi, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Caputo, A.; Zampiron, A.; Carrara, M. Synthesis and Biological Evaluation of 3-Alkoxy Analogues of Flavone-8-acetic Acid. J. Med. Chem. 2003, 46, 3662-3669.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>112</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>196</sb:first-page>
                              <sb:last-page>208</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Li, Y.; Yang, F.; Wang, L.; Cao, Z.; Han, T.; Duan, Z.; Li, Z., Zhao, W. Phosphoramidate Protides of Five Flavones and their Antiproliferative Activity against HepG2 and L-O2 Cell Lines. Eur. J. Med Chem. 2016, 112, 196-208.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Beutler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hamel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Vlietinck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Haemers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Roitman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Cardellina</ce:surname>
                                 <ce:suffix>II</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Boyd</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-activity requirements for flavone cytotoxicity and binding to tubulin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2333</sb:first-page>
                              <sb:last-page>2338</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">Beutler, J. A.; Hamel, E.; Vlietinck, A. J.; Haemers, A.; Rajan, P.; Roitman, J. N.; Cardellina II, J. H.; Boyd, M. R. Structure-Activity Requirements for Flavone Cytotoxicity and Binding to Tubulin. J. Med. Chem. 1998, 41, 2333-2338.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Juvale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Stefan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wiese</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>67</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>115</sb:first-page>
                              <sb:last-page>126</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Juvale, K.; Stefan, K.; Wiese, M. Synthesis and Biological Evaluation of Flavones and Benzoflavones as Inhibitors of BCRP/ABCG2. Eur. J. Med. Chem. 2013, 67, 115-126.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.H.E.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-T.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>161</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>559</sb:first-page>
                              <sb:last-page>580</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">Hassan, A. H. E.; Lee, K.-T.; Lee, Y. S. Eur. J. Med. Chem. 2019, 161, 559-580.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.H.E.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Yoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Yoo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.I.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-S.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-T.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>187</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111965</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Hassan, A. H. E.; Choi, E.; Yoon, Y. M.; Lee, K. W.; Yoo, S. Y.; Cho, M. C.; Yang, J. S.; Kim, H. I.; Hong, J. Y.; Shin, J.-S.; Chung, K. S.; Lee, J.-H.; Lee, K.-T.; Lee, Y. S. Eur. J. Med. Chem. 2020, 187, 111965</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ferraris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Duvall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rojas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Majer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hashimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tsukamoto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of d-amino acid oxidase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3357</sb:first-page>
                              <sb:last-page>3359</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Ferraris, D.; Duvall, B.; Ko, Y.; Thomas, A. G.; Rojas, C.; Majer, P.; Hashimoto, K.; Tsukamoto, T. Synthesis and Biological Evaluation of d-Amino Acid Oxidase Inhibitors. J. Med. Chem. 2008, 51, 3357-3359.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>